Publications

2023

  1. Arriaga MB, Araújo-Pereira M, Andrade VMB, Queiroz ATL, Fernandes CD, Sales C, Aliaga JG, Shivakoti R, Lecca L, Calderon RI, Andrade BB. Influence of dietary pattern on anti-tuberculosis treatment outcomes in persons with dysglycemia: a Peruvian prospective cohort study. Front Nutr. 2023 Dec 18;10:1254983. doi: 10.3389/fnut.2023.1254983. PMID: 38164414; PMCID: PMC10757910.

  2. Amaral EP, Namasivayam S, Queiroz ATL, Fukutani E, Hilligan KL, Aberman K, Fisher L, Bomfim CCB, Kauffman K, Buchanan J, Santuo L, Gazzinelli-Guimaraes PH, Costa DL, Teixeira MA, Barreto-Duarte B, Rocha CG, Santana MF, Cordeiro-Santos M, Barber DL, Wilkinson RJ, Kramnik I, Igarashi K, Scriba T, Mayer-Barber KD, Andrade BB, Sher A. BACH1 promotes tissue necrosis and Mycobacterium tuberculosis susceptibility. Nat Microbiol. 2023 Dec 8. doi: 10.1038/s41564-023-01523-7. Epub ahead of print. PMID: 38066332.

  3. Araújo-Pereira M, Andrade BB. Atorvastatin to reduce bacillary load and attenuate lung damage in TB patients. Int J Tuberc Lung Dis. 2023 Dec 1;27(12):880-881. doi: 10.5588/ijtld.23.0503. PMID: 38042973.

  4. du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ. Standards for clinical trials for treating TB. Int J Tuberc Lung Dis. 2023 Dec 1;27(12):885-898. doi: 10.5588/ijtld.23.0341. PMID: 38042969; PMCID: PMC10719894.

  5. Kengo A, Nabisere R, Gausi K, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Denti P, Sekaggya-Wiltshire C. Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043023. doi: 10.1128/aac.00430-23. Epub 2023 Oct 18. PMID: 37850738; PMCID: PMC10648962.

  6. Hill PC, Cobelens F, Martinez L, Behr MA, Churchyard G, Evans T, Fiore-Gartland AJ, Garcia-Basteiro AL, Hanekom W, Rangaka MX, Vekemans J, White RG. An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine Trials. J Infect Dis. 2023 Nov 2;228(9):1150-1153. doi: 10.1093/infdis/jiad356. PMID: 37607272.

  7. Kengo A, Gausi K, Nabisere R, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Sekaggya-Wiltshire C, Denti P. Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043123. doi: 10.1128/aac.00431-23. Epub 2023 Oct 18. PMID: 37850737; PMCID: PMC10649026.

  8. Geiger K, Patil A, Budhathoki C, Dooley KE, Lowensen K, Ndjeka N, Ngozo J, Farley JE. Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity. J Acquir Immune Defic Syndr. 2023 Nov 1;94(3):253-261. doi: 10.1097/QAI.0000000000003268. PMID: 37757847; PMCID: PMC10592374.

  9. Hill PC, Cobelens F, Martinez L, Garcia-Basteiro A, Behr M, Rangaka MX, Churchyard G, Evans T, Hanekom W, White R. Correspondence Regarding: McShane H. Improving TB vaccine trial efficiency: A tough nut to crack. J Infect Dis. 2023. J Infect Dis. 2023 Oct 28:jiad466. doi: 10.1093/infdis/jiad466. Epub ahead of print. PMID: 37897697.

  10. Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Herna Sari A, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. Lancet. 2023 Oct 21;402(10411):1473-1498. doi: 10.1016/S0140-6736(23)01379-X. Epub 2023 Sep 13. PMID: 37716363.

  11. Wasmann RE, Masini T, Viney K, Verkuijl S, Brands A, Hesseling AC, McIlleron H, Denti P, Dooley KE. A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis. Front Pharmacol. 2023 Apr 25;14:1055329. doi: 10.3389/fphar.2023.1055329. PMID: 37180707; PMCID: PMC10167634.

  12. Nelson KN, Churchyard G, Cobelens F, Hanekom WA, Hill PC, Lopman B, Mave V, Rangaka MX, Vekemans J, White RG, Wong EB, Martinez L, García-Basteiro AL. Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how? Lancet Microbe. 2023 Aug;4(8):e651-e656. doi: 10.1016/S2666-5247(23)00112-X. Epub 2023 Jun 14. PMID: 37329893; PMCID: PMC10393779.

  13. Krishnan S, Wu X, Kim S, McIntire K, Naini L, Hughes MD, Dawson R, Mave V, Gaikwad S, Sanchez J, Mendoza-Ticona A, Gonzales P, Comins K, Shenje J, Fontain SN, Omozoarhe A, Mohapi L, Lalloo UG, Garcia Ferreira AC, Mugah C, Harrington M, Shah NS, Hesseling AC, Churchyard G, Swindells S, Gupta A; AIDS Clinical Trials Group A5300/International Maternal Pediatric Adolescent AIDS Clinical Trials I2003 Protecting Households on Exposure to Newly Diagnosed Index Multidrug-resistant Tuberculosis Patients Feasibility Study Team* (Additional study group members are listed in the Acknowledgment section). 1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2023 Sep 18;77(6):892-900. doi: 10.1093/cid/ciad301. PMID: 37227925; PMCID: PMC10681643.

  14. Verboven L, Callens S, Black J, Maartens G, Dooley KE, Potgieter S, Cartuyvels R; SMARTT team; Laukens K, Warren RM, Van Rie A. A machine-learning based model for automated recommendation of individualized treatment of rifampicin-resistant tuberculosis. Res Sq [Preprint]. 2023 Feb 16:rs.3.rs-2525765. doi: 10.21203/rs.3.rs-2525765/v1. PMID: 36824956; PMCID: PMC9949242.

  15. Dooley KE, Hendricks B, Gupte N, Barnes G, Narunsky K, Whitelaw C, Smit T, Ignatius EH, Friedman A, Dorman SE, Dawson R; Assessing Pretomanid for Tuberculosis (APT) Study Team. Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results. Am J Respir Crit Care Med. 2023 Apr 1;207(7):929-935. doi: 10.1164/rccm.202208-1475OC. PMID: 36455068.

  16. Naidoo A, Dooley KE. Dolutegravir once daily with rifampicin for HIV and tuberculosis. Lancet HIV. 2023 Jul;10(7):e422-e423. doi: 10.1016/S2352-3018(23)00115-7. Epub 2023 May 22. PMID: 37230100; PMCID: PMC10594392.

  17. Kawuma AN, Wasmann RE, Dooley KE, Maartens G, Denti P. Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model. Br J Clin Pharmacol. 2023 Mar;89(3):1216-1221. doi: 10.1111/bcp.15604. Epub 2022 Dec 1. PMID: 36385424

  18. Deshmukh S, Sane M, Gaikwad S, Sahasrabudhe T, Barthwal M, Lokhande R, Raskar S, Kagal A, Dharmshale S, Pradhan N, Gupte A, Alfarisi O, Gupta A, Dooley KE, Gupte N, Golub JE, Mave V. Sex Differences in TB Clinical Presentation, Drug Exposure, and Treatment Outcomes in India. Chest. 2023 Apr;163(4):778-789. doi: 10.1016/j.chest.2022.09.024. Epub 2022 Sep 26. PMID: 36174745; PMCID: PMC10258435.

  19. Martinson NA, Nonyane BAS, Genade LP, Berhanu RH, Naidoo P, Brey Z, Kinghorn A, Nyathi S, Young K, Hausler H, Connell L, Lutchminarain K, Swe Swe-Han K, Vreede H, Said M, von Knorring N, Moulton LH, Lebina L; TUTT Trial team. Evaluating systematic targeted universal testing for tuberculosis in primary care clinics of South Africa: A cluster-randomized trial (The TUTT Trial). PLoS Med. 2023 May 22;20(5):e1004237. doi: 10.1371/journal.pmed.1004237. PMID: 37216385; PMCID: PMC10263318.

  20. Audet CM, Seabi T, Ngobeni S, Berhanu RH, Wagner RG. Pulmonary tuberculosis vs. Tindzhaka and Mafularha: A mixed methods inquiry of traditional healers' perceptions of tuberculosis in rural South Africa. PLOS Glob Public Health. 2023 Apr 21;3(4):e0001611. doi: 10.1371/journal.pgph.0001611. PMID: 37083848; PMCID: PMC10121049.

  21. Berhanu RH, Lebina L, Nonyane BAS, Milovanovic M, Kinghorn A, Connell L, Nyathi S, Young K, Hausler H, Naidoo P, Brey Z, Shearer K, Genade L, Martinson NA. Yield of Facility-based Targeted Universal Testing for Tuberculosis With Xpert and Mycobacterial Culture in High-Risk Groups Attending Primary Care Facilities in South Africa. Clin Infect Dis. 2023 May 3;76(9):1594-1603. doi: 10.1093/cid/ciac965. PMID: 36610730; PMCID: PMC10156124

  22. Gupta A, Singh P, Aaron L, Montepiedra G, Chipato T, Stranix-Chibanda L, Chanaiwa V, Vhembo T, Mutambanengwe M, Masheto G, Raesi M, Bradford S, Golner A, Costello D, Kulkarni V, Shayo A, Kabugho E, Jean-Phillippe P, Chakhtoura N, Sterling TR, Theron G, Weinberg A; IMPAACT P1078 TB APPRISE Study Team. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. Lancet Child Adolesc Health. 2023 Aug 24:S2352-4642(23)00174-8. doi: 10.1016/S2352-4642(23)00174-8. Epub ahead of print. PMID: 37634517.

  23. Sack DE, Brantley M, Ratliff M, Mathieson S, Turner M, Pettit AC, Sterling TR, Rebeiro PF. Misclassification of Loss to Care Among Persons with HIV: Improved Capture of Silent Transfers through Surveillance Linkage using Statewide Mandatorily Reported Laboratory Measures. Clin Infect Dis. 2023 Aug 9:ciad461. doi: 10.1093/cid/ciad461. Epub ahead of print. PMID: 37555632.

  24. Ryckman T, Weiser J, Gombe M, Turner K, Soni P, Tarlton D, Mazhidova N, Churchyard G, Chaisson RE, Dowdy DW. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis. Lancet Glob Health. 2023 Aug;11(8):e1205-e1216. doi: 10.1016/S2214-109X(23)00251-6. PMID: 37474228; PMCID: PMC10369017.

  25. Agyemang N, Scarsi KK, Baker P, Smeaton LM, Podany AT, Olefsky M, Woolley E, Barr E, Pham M, Mawlana S, Supparatpinyo K, Gatechompol S, Jalil EM, Gadama L, Badal-Faesen S, Van Schalkwyk M, Kayama C, Belaunzaran-Zamudio PF, Godfrey C, Cohn SE, Mngqibisa R, Haas DW; AIDS Clinical Trials Group A5375 Study Team. Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis. Pharmacogenet Genomics. 2023 Aug 1;33(6):126-135. doi: 10.1097/FPC.0000000000000501. Epub 2023 Jun 12. PMID: 37306344; PMCID: PMC10309098.

  26. Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States. Ann Am Thorac Soc. 2023 Sep;20(9):1258-1266. doi: 10.1513/AnnalsATS.202212-1005OC. PMID: 37159954.

  27. Schwalb A, Bergstrom M, Woodd S, Rehman AM, PrayGod G, Kasonka L, Koethe JR, Filteau S, Houben RMGJ. Impact of micro- and macronutrient status on the incidence of tuberculosis: An examination of an African cohort initiating antiretroviral therapy. PLOS Glob Public Health. 2023 Jul 13;3(7):e0002007. doi: 10.1371/journal.pgph.0002007. PMID: 37440476; PMCID: PMC10343057.

  28. Malhotra A, Nonyane BAS, Shirey E, Mulder C, Hippner P, Mulatu F, Ratshinanga A, Mitiku P, Cohn S, Conradie G, Chihota V, Chaisson RE, Churchyard GJ, Golub J, Dowdy D, Sohn H, Charalambous S, Bedru A, Salazar-Austin N. Pragmatic cluster-randomized trial of home-based preventive treatment for TB in Ethiopia and South Africa (CHIP-TB). Trials. 2023 Jul 25;24(1):475. doi: 10.1186/s13063-023-07514-7. PMID: 37491264; PMCID: PMC10367260.

  29. Davies LRL, Smith MT, Cizmeci D, Fischinger S, Shih-Lu Lee J, Lu LL, Layton ED, Grant AD, Fielding K, Stein CM, Boom WH, Hawn TR, Fortune SM, Wallis RS, Churchyard GJ, Alter G, Seshadri C. IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners. EBioMedicine. 2023 Jul;93:104678. doi: 10.1016/j.ebiom.2023.104678. Epub 2023 Jun 26. PMID: 37379655; PMCID: PMC10320233.

  30. Araújo-Pereira M, Krishnan S, Salgame P, Manabe YC, Hosseinipour MC, Bisson G, Severe DP, Rouzier V, Leong S, Mave V, Sawe FK, Siika AM, Kanyama C, Dadabhai SS, Lama JR, Valencia-Huamani J, Badal-Faesen S, Lalloo UG, Naidoo K, Mohapi L, Kityo C, Andrade BB, Gupta A. Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial. EClinicalMedicine. 2023 Jun 2;60:102030. doi: 10.1016/j.eclinm.2023.102030. PMID: 37287871; PMCID: PMC10242630.

  31. Maenetje P, Baik Y, Schramm DB, Vangu MDW, Wallis RS, Mlotshwa M, Tiemessen CT, Li Y, Kornfeld H, Churchyard G, Auld SC, Bisson GP. Circulating biomarkers, FeNO, and lung function in patients with HIV and tuberculosis. J Infect Dis. 2023 Jun 30:jiad232. doi: 10.1093/infdis/jiad232. Epub ahead of print. PMID: 37386883.

  32. Krause R, Warren CM, Simmons JD, Rebeiro PF, Maruri F, Karim F, Sterling TR, Koethe JR, Leslie A, van der Heijden YF. Failure to decrease HbA1c levels following TB treatment is associated with elevated Th1/Th17 CD4+ responses. Front Immunol. 2023 May 29;14:1151528. doi: 10.3389/fimmu.2023.1151528. PMID: 37313404; PMCID: PMC10258338.

  33. Queiroz ATL, Vinhaes CL, Fukutani ER, Gupte AN, Kumar NP, Fukutani KF, Arriaga MB, Sterling TR, Babu S, Gaikwad S, Karyakarte R, Mave V, Paradhkar M, Viswanathan V, Gupta A, Andrade BB, Kornfeld H; RePORT Brazil; RePORT India Consortia. A multi-center, prospective cohort study of whole blood gene expression in the tuberculosis-diabetes interaction. Sci Rep. 2023 May 12;13(1):7769. doi: 10.1038/s41598-023-34847-9. PMID: 37173394; PMCID: PMC10180618.

  34. Araújo-Pereira M, Nogueira BMF, Spener-Gomes R, Carvalho ACC, Sant'Anna FM, Figueiredo MC, Turner MM, Kritski AL, Cordeiro-Santos M, Rolla VC, Sterling TR, Andrade BB; RePORT-Brazil Consortium. Anemia and anti-tuberculosis treatment outcome in persons with pulmonary tuberculosis: A multi-center prospective cohort study. J Infect Public Health. 2023 Jun;16(6):974-980. doi: 10.1016/j.jiph.2023.04.009. Epub 2023 Apr 18. PMID: 37121049; PMCID: PMC10194045.

  35. Araújo-Pereira M, Schutz C, Barreto-Duarte B, Barr D, Villalva-Serra K, Vinhaes CL, Ward A, Meintjes G, Andrade BB. Interplay between systemic inflammation, anemia, and mycobacterial dissemination and its impact on mortality in TB-associated HIV: a prospective cohort study. Front Immunol. 2023 Apr 18;14:1177432. doi: 10.3389/fimmu.2023.1177432. PMID: 37143662; PMCID: PMC10151654.

  36. van der Heijden YF, Maruri F, Blackman A, Morrison R, Guo Y, Sterling TR. Mycobacterium tuberculosis Gene Expression Associated With Fluoroquinolone Resistance and Efflux Pump Inhibition. J Infect Dis. 2023 Aug 16;228(4):469-478. doi: 10.1093/infdis/jiad112. PMID: 37079382; PMCID: PMC10428193.

  37. Rangaka MX, Frick M, Churchyard G, García-Basteiro AL, Hatherill M, Hanekom W, Hill PC, Hamada Y, Quaife M, Vekemans J, White RG, Cobelens F. Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment. Lancet Respir Med. 2023 Apr;11(4):380-390. doi: 10.1016/S2213-2600(23)00084-X. Epub 2023 Mar 23. PMID: 36966794.

  38. Kim S, Hesseling AC, Wu X, Hughes MD, Shah NS, Gaikwad S, Kumarasamy N, Mitchell E, Leon M, Gonzales P, Badal-Faesen S, Lourens M, Nerette S, Shenje J, de Koker P, Nedsuwan S, Mohapi L, Chakalisa UA, Mngqbisa R, Escada RODS, Ouma S, Heckman B, Naini L, Gupta A, Swindells S, Churchyard G; ACTG A5300/IMPAACT 2003 PHOENIx Feasibility Study Team. Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household. PLoS One. 2023 Mar 17;18(3):e0283290. doi: 10.1371/journal.pone.0283290. PMID: 36930628; PMCID: PMC10022776.

  39. Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 Sep;11(9):782-790. doi: 10.1016/S2213-2600(23)00096-6. Epub 2023 Mar 23. PMID: 36966788.

  40. Baik Y, Maenetje P, Schramm D, Tiemessen C, Ncube I, Churchyard G, Wallis R, Vangu MD, Kornfeld H, Li Y, Auld SC, Bisson GP. Lung function and collagen 1a levels are associated with changes in 6 min walk test distance during treatment of TB among HIV-infected adults: a prospective cohort study. BMC Pulm Med. 2023 Feb 3;23(1):53. doi: 10.1186/s12890-023-02325-7. PMID: 36737697; PMCID: PMC9896708.

  41. Jarrett RT, van der Heijden Y, Shotwell MS, Chihota V, Marzinke MA, Chaisson RE, Dooley KE, Churchyard GJ. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0129722. doi: 10.1128/aac.01297-22. Epub 2023 Jan 9. PMID: 36622148; PMCID: PMC9933705.

  42. Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S; Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 Feb 8;76(3):e580-e589. doi: 10.1093/cid/ciac707. PMID: 36041016; PMCID: PMC10169427.

  43. Sant Anna FM, Araújo-Pereira M, Schmaltz CAS, Arriaga MB, Andrade BB, Rolla VC. Impact of adverse drug reactions on the outcomes of tuberculosis treatment. PLoS One. 2023 Feb 7;18(2):e0269765. doi: 10.1371/journal.pone.0269765. PMID: 36749743; PMCID: PMC9904486.

  44. Pietersen E, Anderson K, Cox H, Dheda K, Bian A, Shepherd BE, Sterling TR, Warren RM, van der Heijden YF. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa. PLoS One. 2023 Feb 13;18(2):e0281097. doi: 10.1371/journal.pone.0281097. PMID: 36780443; PMCID: PMC9925007.

  45. Peters JS, McIvor A, Papadopoulos AO, Masangana T, Gordhan BG, Waja Z, Otwombe K, Letutu M, Kamariza M, Sterling TR, Bertozzi CR, Martinson NA, Kana BD. Differentially culturable tubercle bacteria as a measure of tuberculosis treatment response. Front Cell Infect Microbiol. 2023 Jan 12;12:1064148. doi: 10.3389/fcimb.2022.1064148. PMID: 36710965; PMCID: PMC9877613.

  46. Otero L, Zetola N, Campos M, Zunt J, Bayer A, Curisinche M, Ochoa T, Reyes M, Vega V, Van der Stuyft P, Sterling TR. Isoniazid preventive therapy completion in children under 5 years old who are contacts of tuberculosis cases in Lima, Peru: study protocol for an open-label, cluster-randomized superiority trial. Trials. 2023 Jan 24;24(1):54. doi: 10.1186/s13063-022-07062-6. PMID: 36694242; PMCID: PMC9871424.

2022

  1. Holzman SB, Perry A, Saleeb P, Pyan A, Keh C, Salcedo K, Narita M, Ahmed A, Miller TL, Pettit AC, Khurana R, Whipple M, Katz D, Largen A, Krueger A, Shah M; Tuberculosis Epidemiologic Studies Consortium. Evaluation of the Latent Tuberculosis Care Cascade Among Public Health Clinics in the United States. Clin Infect Dis. 2022 Nov 14;75(10):1792-1799. doi: 10.1093/cid/ciac248. PMID: 35363249.

  2. Naidoo A, Dooley KE, Naidoo K, Padayatchi N, Yende-Zuma N, Perumal R, Dorse G, Boodhram R, Osuala EC. INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial. BMJ Open. 2022 Nov 10;12(11):e067765. doi: 10.1136/bmjopen-2022-067765. PMID: 36356989; PMCID: PMC9660663.

  3. Jones AJ, Mathad JS, Dooley KE, Eke AC. Evidence for Implementation: Management of TB in HIV and Pregnancy. Curr HIV/AIDS Rep. 2022 Dec;19(6):455-470. doi: 10.1007/s11904-022-00641-x. Epub 2022 Oct 29. PMID: 36308580; PMCID: PMC9617238.

  4. Bezerra AL, Moreira ADSR, Isidoro-Gonçalves L, Lara CFDS, Amorim G, Silva EC, Kritski AL, Carvalho ACC. Clinical, laboratory, and radiographic aspects of patients with pulmonary tuberculosis and dysglycemia and tuberculosis treatment outcomes. J Bras Pneumol. 2022 Nov 28;48(6):e20210505. doi: 10.36416/1806-3756/e20210505. PMID: 36449815; PMCID: PMC9747138.

  5. Sobral L, Arriaga MB, Souza AB, Araújo-Pereira M, Barreto-Duarte B, Sales C, Rocha MS, Benjamin A, Moreira ASR, de Oliveira JG, Carvalho AC, Spener-Gomes R, Figueiredo MC, Cavalcante S, Durovni B, Lapa-E-Silva JR, Kritski AL, Rolla VC, Sterling TR, Cordeiro-Santos M, Andrade BB. Determinants of losses in the tuberculosis infection cascade of care among children and adolescent contacts of pulmonary tuberculosis cases: A Brazilian multi-centre longitudinal study. Lancet Reg Health Am. 2022 Nov;15:100358. doi: 10.1016/j.lana.2022.100358. Epub 2022 Aug 23. PMID: 36438860; PMCID: PMC9696515.

  6. Nogueira BMF, Krishnan S, Barreto-Duarte B, Araújo-Pereira M, Queiroz ATL, Ellner JJ, Salgame P, Scriba TJ, Sterling TR, Gupta A, Andrade BB. Diagnostic biomarkers for active tuberculosis: progress and challenges. EMBO Mol Med. 2022 Oct 31:e14088. doi: 10.15252/emmm.202114088. Epub ahead of print. PMID: 36314872.

  7. Villalva-Serra K, Barreto-Duarte B, Nunes VM, Menezes RC, Rodrigues MMS, Queiroz ATL, Arriaga MB, Cordeiro-Santos M, Kritski AL, Sterling TR, Araújo-Pereira M, Andrade BB. Tuberculosis treatment outcomes of diabetic and non-diabetic TB/HIV co-infected patients: A nationwide observational study in Brazil. Front Med (Lausanne). 2022 Sep 16;9:972145. doi: 10.3389/fmed.2022.972145. PMID: 36186793; PMCID: PMC9523014.

  8. Miner MD, Hatherill M, Mave V, Gray GE, Nachman S, Read SW, White RG, Hesseling A, Cobelens F, Patel S, Frick M, Bailey T, Seder R, Flynn J, Rengarajan J, Kaushal D, Hanekom W, Schmidt AC, Scriba TJ, Nemes E, Andersen-Nissen E, Landay A, Dorman SE, Aldrovandi G, Cranmer LM, Day CL, Garcia-Basteiro AL, Fiore-Gartland A, Mogg R, Kublin JG, Gupta A, Churchyard G. Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel. Lancet HIV. 2022 Nov;9(11):e791-e800. doi: 10.1016/S2352-3018(22)00255-7. Epub 2022 Oct 11. Erratum in: Lancet HIV. 2022 Dec;9(12):e822. PMID: 36240834; PMCID: PMC9667733.

  9. Van Rie A, De Vos E, Costa E, Verboven L, Ndebele F, Heupink TH, Abrams S; SMARTT team; Fanampe B, Van der Spoel Van Dyk A, Charalambous S, Churchyard G, Warren R. Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial. Trials. 2022 Oct 8;23(1):864. doi: 10.1186/s13063-022-06793-w. PMID: 36209235; PMCID: PMC9548157.

  10. Cubillos-Angulo JM, Nogueira BMF, Arriaga MB, Barreto-Duarte B, Araújo-Pereira M, Fernandes CD, Vinhaes CL, Villalva-Serra K, Nunes VM, Miguez-Pinto JP, Amaral EP, Andrade BB. Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs. Front Med (Lausanne). 2022 Sep 23;9:970408. doi: 10.3389/fmed.2022.970408. PMID: 36213651; PMCID: PMC9537567.

  11. Guo Y, van der Heijden YF, Maruri F, Jiang L, Morrison R, Sterling TR. RNA editing in Mycobacterium tuberculosis. Microbiol Res. 2022 Nov;264:127174. doi: 10.1016/j.micres.2022.127174. Epub 2022 Aug 23. PMID: 36067705.

  12. Ntshiqa T, Chihota V, Mansukhani R, Nhlangulela L, Velen K, Charalambous S, Maenetje P, Hawn TR, Wallis R, Grant AD, Fielding K, Churchyard G. Comparing QuantiFERON-TB Gold Plus with QuantiFERON-TB Gold in-tube for diagnosis of latent tuberculosis infection among highly TB exposed gold miners in South Africa. Gates Open Res. 2022 Aug 18;5:66. doi: 10.12688/gatesopenres.13191.3. PMID: 37560544; PMCID: PMC10407057.

  13. Schwalb A, Cachay R, Wright A, Phillips PPJ, Kaur P, Diacon AH, Ugarte-Gil C, Mitnick CD, Sterling TR, Gotuzzo E, Horsburgh CR. Factors associated with screening failure and study withdrawal in multidrug-resistant TB. Int J Tuberc Lung Dis. 2022 Sep 1;26(9):820-825. doi: 10.5588/ijtld.21.0729. PMID: 35996282.

  14. Lang R, Humes E, Hogan B, Lee J, D'Agostino R, Massaro J, Kim A, Meigs JB, Borowsky L, He W, Lyass A, Cheng D, Kim HN, Klein MB, Cachay ER, Bosch RJ, Gill MJ, Silverberg MJ, Thorne JE, McGinnis K, Horberg MA, Sterling TR, Triant VA, Althoff KN. Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection. J Am Heart Assoc. 2022 Sep 21:e026473. doi: 10.1161/JAHA.122.026473. Epub ahead of print. PMID: 36129038.

  15. Schwalb A, Cachay R, Wright A, Phillips PPJ, Kaur P, Diacon AH, Ugarte-Gil C, Mitnick CD, Sterling TR, Gotuzzo E, Horsburgh CR. Factors associated with screening failure and study withdrawal in multidrug-resistant TB. Int J Tuberc Lung Dis. 2022 Sep 1;26(9):820-825. doi: 10.5588/ijtld.21.0729. PMID: 35996282.

  16. Pettit AC, Phillips PP, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S; Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349). Clin Infect Dis. 2022 Aug 30:ciac707. doi: 10.1093/cid/ciac707. Epub ahead of print. PMID: 36041016.

  17. Magohe A, Kimario J, Lukmanji Z, Hendricks K, Koethe JR, Neke NM, Tvaroha S, Connor R, Mackenzie T, Waddell R, Maro I, Matee M, Pallangyo K, Bakari M, Horsburgh CR, von Reyn CF. Randomized, controlled trial of a protein-calorie supplement for women coinfected with HIV-TB. Int J Tuberc Lung Dis. 2022 Aug 1;26(8):798-800. doi: 10.5588/ijtld.21.0669. PMID: 35898141.

  18. Anderson K, Pietersen E, Dheda K, van der Heijden YF. Comparison of treatment outcome definitions in drug-resistant tuberculosis patients with high incidence of acquired second-line drug resistance. Afr J Thorac Crit Care Med. 2022 Jul 15;28(2):10.7196/AJTCCM.2022.v28i2.177. doi: 10.7196/AJTCCM.2022.v28i2.177. PMID: 35991341; PMCID: PMC9379990.

  19. Arriaga MB, Karim F, Queiroz ATL, Araújo-Pereira M, Barreto-Duarte B, Sales C, Moosa MS, Mazibuko M, Milne GL, Maruri F, Serezani CH, Koethe JR, Figueiredo MC, Kritski AL, Cordeiro-Santos M, Rolla VC, Sterling TR, Leslie A, Andrade BB. Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis. Front Immunol. 2022 Jul 8;13:919802. doi: 10.3389/fimmu.2022.919802. PMID: 35874781; PMCID: PMC9304990.

  20. Simmons JD, Dill-McFarland KA, Stein CM, Van PT, Chihota V, Ntshiqa T, Maenetje P, Peterson GJ, Benchek P, Nsereko M, Velen K, Fielding KL, Grant AD, Gottardo R, Mayanja-Kizza H, Wallis RS, Churchyard G, Boom WH, Hawn TR. Monocyte Transcriptional Responses to Mycobacterium tuberculosis Associate with Resistance to Tuberculin Skin Test and Interferon Gamma Release Assay Conversion. mSphere. 2022 Jun 29;7(3):e0015922. doi: 10.1128/msphere.00159-22. Epub 2022 Jun 13. PMID: 35695527; PMCID: PMC9241521. 

  21. Garcia-Basteiro AL, White RG, Tait D, Schmidt AC, Rangaka MX, Quaife M, Nemes E, Mogg R, Hill PC, Harris RC, Hanekom WA, Frick M, Fiore-Gartland A, Evans T, Dagnew AF, Churchyard G, Cobelens F, Behr MA, Hatherill M. End-point definition and trial design to advance tuberculosis vaccine development. Eur Respir Rev. 2022 Jun 7;31(164):220044. doi: 10.1183/16000617.0044-2022. PMID: 35675923; PMCID: PMC9488660.

  22. Wada PY, Costa AG, Araújo-Pereira M, Barreto-Duarte B, Souza AB, Rocha MS, Figueiredo MC, Turner MM, Rolla VC, Kritski AL, Cordeiro-Santos M, Andrade BB, Sterling TR, Rebeiro PF; Regional Prospective Observational Research in Tuberculosis (RePORT) Brazil Consortium. Possible Sex Difference in Latent Tuberculosis Infection Risk among Close Tuberculosis Contacts. Int J Infect Dis. 2022 Jul 14:S1201-9712(22)00426-X. doi: 10.1016/j.ijid.2022.07.031. Epub ahead of print. PMID: 35843494.

  23. Ridolfi F, Peetluk L, Amorim G, Turner M, Figueiredo M, Cordeiro-Santos M, Cavalcante S, Kritski A, Durovni B, Andrade B, Sterling TR, Rolla V; Regional Prospective Observational Research in Tuberculosis (RePORT)–Brazil Consortium. TB TREATMENT OUTCOMES IN BRAZIL: DIFFERENT PREDICTORS FOR EACH TYPE OF UNSUCCESSFUL OUTCOME. Clin Infect Dis. 2022 Jul 5:ciac541. doi: 10.1093/cid/ciac541. Epub ahead of print. PMID: 35788646.

  24. Nguenha D, Acacio S, Murias-Closas A, Ramanlal N, Saavedra B, Karajeanes E, Mudumane B, Mambuque E, Gomes N, Losada I, Oliveras L, Naueia E, Sterling TR, Amorim G, Moon TD, Menéndez C, Vaz P, López-Varela E, Garcia-Basteiro AL. Prevalence and clinical characteristics of pulmonary TB among pregnant and post-partum women. Int J Tuberc Lung Dis. 2022 Jul 1;26(7):641-649. doi: 10.5588/ijtld.21.0567. PMID: 35768920.

  25. Araújo-Pereira M, Barreto-Duarte B, Arriaga MB, Musselwhite LW, Vinhaes CL, Belaunzaran-Zamudio PF, Rupert A, Montaner LJ, Lederman MM, Sereti I, Madero JGS, Andrade BB. Relationship Between Anemia and Systemic Inflammation in People Living With HIV and Tuberculosis: A Sub-Analysis of the CADIRIS Clinical Trial. Front Immunol. 2022 Jun 23;13:916216. doi: 10.3389/fimmu.2022.916216. PMID: 35812431; PMCID: PMC9260499.

  26. Queiroz ATL, Araújo-Pereira M, Barreto-Duarte B, Gomes-Silva A, Costa AG, Andrade AMS, Miguez-Pinto JP, Spener-Gomes R, Souza AB, Benjamin A, Sant'Anna F, Figueiredo MC, Mave V, Salgame P, Ellner JJ, Sterling TR, Cordeiro-Dos-Santos M, Andrade BB, Rolla VC. Immunologic Biomarkers in Peripheral Blood of Persons With Tuberculosis and Advanced HIV. Front Immunol. 2022 Jun 10;13:890003. doi: 10.3389/fimmu.2022.890003. PMID: 35757685; PMCID: PMC9226490.

  27. Porter M, Choshi P, Pedretti S, Chimbetete T, Smith R, Meintjes G, Phillips E, Lehloenya R, Peter J. IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-line Anti-tuberculosis Drugs in an HIV Endemic Setting. J Invest Dermatol. 2022 Jun 1:S0022-202X(22)01500-7. doi: 10.1016/j.jid.2022.05.1059. Epub ahead of print. PMID: 35659939.

  28. Anderson K, Pietersen E, Shepherd BE, Bian A, Dheda K, Warren R, Sterling TR, van der Heijden YF. High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence. HIV Med. 2022 May 24. doi: 10.1111/hiv.13318. Epub ahead of print. PMID: 35608016.

  29. Walker NF, Karim F, Moosa M, Moodley S, Mazibuko M, Khan K, Sterling TR, van der Heijden YF, Grant AD, Elkington PT, Pym A, Leslie A. Elevated Plasma Matrix Metalloproteinase-8 associates with Sputum Culture Positivity in Pulmonary Tuberculosis. J Infect Dis. 2022 May 1:jiac160. doi: 10.1093/infdis/jiac160. Epub ahead of print. PMID: 35510939.

  30. Vesga JF, Lienhardt C, Nsengiyumva P, Campbell JR, Oxlade O, den Boon S, Falzon D, Schwartzman K, Churchyard G, Arinaminpathy N. Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis. BMC Med. 2022 May 18;20(1):182. doi: 10.1186/s12916-022-02378-1. PMID: 35581650; PMCID: PMC9115962.

  31. Bender Ignacio RA, Long J, Saha A, Nguyen FK, Joudeh L, Valinetz E, Mendelsohn SC, Scriba TJ, Hatherill M, Janes H, Churchyard G, Buchbinder S, Duerr A, Shah JA, Hawn TR. Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition. PLoS One. 2022 May 3;17(5):e0267729. doi: 10.1371/journal.pone.0267729. PMID: 35503767; PMCID: PMC9064099.

  32. Antimycobacterial Susceptibility Testing Group. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. Eur Respir J. 2022 Apr 14;59(4):2200166. doi: 10.1183/13993003.00166-2022. PMID: 35422426; PMCID: PMC9059840.

  33. Holzman SB, Perry A, Saleeb P, Pyan A, Keh C, Salcedo K, Narita M, Ahmed A, Miller TL, Pettit AC, Khurana R, Whipple M, Katz D, Largen A, Krueger A, Shah M. Evaluation of the latent tuberculosis care cascade among public health clinics in the United States. Clin Infect Dis. 2022 Apr 1:ciac248. doi: 10.1093/cid/ciac248. Epub ahead of print. PMID: 35363249.

  34. Crabtree-Ramirez B, Jenkins CA, Shepherd BE, Jayathilake K, Veloso VG, Carriquiry G, Gotuzzo E, Cortes CP, Padgett D, McGowan C, Sierra-Madero J, Koenig S, Pape JW, Sterling TR; CCASAnet Region of IeDEA. Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy. BMC Infect Dis. 2022 Apr 5;22(1):341. doi: 10.1186/s12879-022-07330-5. PMID: 35382770; PMCID: PMC8985331.

  35. Mulenga H, Fiore-Gartland A, Mendelsohn SC, Penn-Nicholson A, Mbandi SK, Nemes E, Borate B, Musvosvi M, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS Study Team. Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study. EClinicalMedicine. 2022 Apr 21;47:101396. doi: 10.1016/j.eclinm.2022.101396. PMID: 35497063; PMCID: PMC9046130.

  36. Mendelsohn SC, Mbandi SK, Fiore-Gartland A, Penn-Nicholson A, Musvosvi M, Mulenga H, Fisher M, Hadley K, Erasmus M, Nombida O, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M, Scriba TJ. Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. Commun Med (Lond). 2022;2(1):26. doi: 10.1038/s43856-022-00086-8. Epub 2022 Mar 10. PMID: 35342900; PMCID: PMC8954216.

  37. Chihota VN, Ntshiqa T, Maenetje P, Mansukhani R, Velen K, Hawn TR, Wallis R, Grant AD, Churchyard GJ, Fielding K. Resistance to Mycobacterium tuberculosis infection among highly TB exposed South African gold miners. PLoS One. 2022 Mar 18;17(3):e0265036. doi: 10.1371/journal.pone.0265036. PMID: 35302992; PMCID: PMC8932619.

  38. Mendelsohn SC, Fiore-Gartland A, Awany D, Mulenga H, Mbandi SK, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS-HR Study Team. Clinical predictors of pulmonary tuberculosis among South African adults with HIV. EClinicalMedicine. 2022 Mar 5;45:101328. doi: 10.1016/j.eclinm.2022.101328. PMID: 35274090; PMCID: PMC8902614.

  39. Kim S, Wu X, Hughes MD, Upton C, Narunsky K, Mendoza-Ticona A, Khajenoori S, Gonzales P, Badal-Faesen S, Shenje J, Omoz-Oarhe A, Rouzier V, Garcia-Prats AJ, Demers AM, Naini L, Smith E, Churchyard G, Swindells S, Shah NS, Gupta A, Hesseling AC; ACTG A5300/IMPAACT 2003/PHOENix Feasibility Study Team. High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis. Pediatr Infect Dis J. 2022 May 1;41(5):e194-e202. doi: 10.1097/INF.0000000000003505. PMID: 35239624; PMCID: PMC9007870.

  40. Mulenga H, Fiore-Gartland A, Mendelsohn SC, Penn-Nicholson A, Mbandi SK, Borate B, Musvosvi M, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS Study Team. The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. EBioMedicine. 2022 Mar;77:103886. doi: 10.1016/j.ebiom.2022.103886. Epub 2022 Feb 18. PMID: 35183869; PMCID: PMC8861653.

  41. Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Sebe M, Edward VA, Rassool M, Ahmed K, Fielding K, Ahidjo BA, Vangu MDT, Churchyard G. Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial. PLoS One. 2022 Feb 4;17(2):e0252097. doi: 10.1371/journal.pone.0252097. PMID: 35120127; PMCID: PMC8815935.

  42. Singer SN, Ndumnego OC, Kim RS, Ndung'u T, Anastos K, French A, Churchyard G, Paramithiothis E, Kasprowicz VO, Achkar JM. Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIV. EBioMedicine. 2022 Jan;75:103787. doi: 10.1016/j.ebiom.2021.103787. Epub 2021 Dec 27. PMID: 34968761; PMCID: PMC8718743.

  43. Arriaga MB, Araújo-Pereira M, Barreto-Duarte B, Sales C, Miguez-Pinto JP, Nogueira EB, Nogueira BMF, Rocha MS, Souza AB, Benjamin A, de Oliveira JG, Moreira ASR, Queiroz ATL, Rodrigues MMS, Spener-Gomes R, Figueiredo MC, Durovni B, Cavalcante S, Lapa-E-Silva JR, Kristki AL, Cordeiro-Santos M, Sterling TR, Rolla VC, Andrade BB; RePORT-Brazil consortium. Prevalence and Clinical Profiling of Dysglycemia and HIV Infection in Persons With Pulmonary Tuberculosis in Brazil. Front Med (Lausanne). 2022 Jan 21;8:804173. doi: 10.3389/fmed.2021.804173. PMID: 35127760; PMCID: PMC8814308.

  44. Pietersen E, Anderson K, van der Heijden YF. Public health and hospital-based nursing intersection: Case study of drug-resistant tuberculosis patients. Public Health Nurs. 2022 Jan;39(1):170-179. doi: 10.1111/phn.13042. Epub 2022 Jan 6. PMID: 34990027; PMCID: PMC8766955.

  45. Haas DW, Abdelwahab MT, van Beek SW, Baker P, Maartens G, Bradford Y, Ritchie MD, Wasserman S, Meintjes G, Beeri K, Gandhi NR, Svensson EM, Denti P, Brust JCM. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. J Infect Dis. 2022 Jan 29:jiac024. doi: 10.1093/infdis/jiac024. Epub ahead of print. PMID: 35091749.

  46. Calderon RI, Arriaga MB, Aliaga JG, Barreda NN, Sanabria OM, Barreto-Duarte B, Franco JPD, Lecca L, Andrade BB, Carvalho ACC, Kritski AL. Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru. Int J Infect Dis. 2022 Jan 13:S1201-9712(22)00013-3. doi: 10.1016/j.ijid.2022.01.012. Epub ahead of print. PMID: 35033658

2021

  1. Mulenga H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, Kimbung Mbandi S, Fiore-Gartland A, Tameris M, Mabwe S, Africa H, Bilek N, Kafaar F, Khader SA, Carstens B, Hadley K, Hikuam C, Erasmus M, Jaxa L, Raphela R, Nombida O, Kaskar M, Nicol MP, Mbhele S, Van Heerden J, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Walzl G, Naidoo K, Churchyard G, Hatherill M, Scriba TJ; CORTIS Study Team. Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. Am J Respir Crit Care Med. 2021 Dec 15;204(12):1463-1472. doi: 10.1164/rccm.202103-0548OC. PMID: 34520313

  2. Singhania A, Dubelko P, Kuan R, Chronister WD, Muskat K, Das J, Phillips EJ, Mallal SA, Seumois G, Vijayanand P, Sette A, Lerm M, Peters B, Lindestam Arlehamn C. CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature. EBioMedicine. 2021 Dec;74:103746. doi: 10.1016/j.ebiom.2021.103746. Epub 2021 Dec 11. PMID: 34902786; PMCID: PMC8671872

  3. Costa AG, Carvalho BKS, Araújo-Pereira M, Ibiapina HNS, Spener-Gomes R, Souza AB, Gomes-Silva A, Andrade AMS, Silva EC, Arriaga MB, Benjamin A, Rocha MS, Moreira ASR, Oliveira JG, Figueiredo MC, Turner MM, Durovni B, Cavalcante S, Kritski AL, Rolla VC, Sterling TR, Andrade BB, Cordeiro-Santos M; RePORT-Brazil Consortium. Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil. Microbiol Spectr. 2021 Dec 22;9(3):e0116321. doi: 10.1128/Spectrum.01163-21. Epub 2021 Dec 1. PMID: 34851140; PMCID: PMC8635161

  4. Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, Marx FM, Meghji J, Pedrazzoli D, Salomon JA, Sweeney S, van Kampen SC, Wallis RS, Houben RMGJ, Cohen T. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Glob Health. 2021 Dec;9(12):e1679-e1687. doi: 10.1016/S2214-109X(21)00367-3. PMID: 34798027; PMCID: PMC8609280

  5. Pearlman SI, Tang EM, Tao YK, Haselton FR. Controlling Droplet Marangoni Flows to Improve Microscopy-Based TB Diagnosis. Diagnostics (Basel). 2021 Nov 21;11(11):2155. doi: 10.3390/diagnostics11112155. PMID: 34829502; PMCID: PMC8618690

  6. Schwalb A, Cachay R, Meza E, Cáceres T, Blackman A, Maruri F, Sterling TR, Gotuzzo E. Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru. BMC Res Notes. 2021 Nov 14;14(1):413. doi: 10.1186/s13104-021-05832-0. PMID: 34776013; PMCID: PMC8591909

  7. Weinberg A, Aaron L, Montepiedra G, Sterling TR, Browning R, Mmbaga B, Vhembo T, Naik S, Kabugho E, Masheto G, Pahwa S, Mathad JS, LaCourse SM, McCarthy K, Bradford S, Theron G, Costello D, Zimmer B, Pierre MF, Gausi K, Denti P, Haas DW, Gupta A; IMPAACT P1078 study team. Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. Clin Infect Dis. 2021 Nov 2;73(9):e3555-e3562. doi: 10.1093/cid/ciaa1083. PMID: 32720695; PMCID: PMC8563205

  8. van der Heijden YF, Zhang B, Chougnet CA, Huaman MA. Cytomegalovirus Infection Is Associated With Increased Prevalence of Latent Tuberculosis Infection. Open Forum Infect Dis. 2021 Oct 23;8(11):ofab539. doi: 10.1093/ofid/ofab539. PMID: 35198641; PMCID: PMC8855520.

  9. Radtke KK, Ernest JP, Zhang N, Ammerman NC, Nuermberger E, Belknap R, Boyd R, Sterling TR, Savic RM. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0170521. doi: 10.1128/AAC.01705-21. Epub 2021 Oct 4. PMID: 34606336; PMCID: PMC8597776

  10. Gupte AN, Kumar P, Araújo-Pereira M, Kulkarni V, Paradkar M, Pradhan N, Menon P, Chandrasekaran PD, Hanna LE, Yogendra Shivakumar SVB, Rockwood N, Du Bruyn E, Karyakarte R, Gaikwad S, Bollinger R, Golub J, Gupte N, Viswanathan V, Wilkinson RJ, Mave V, Babu S, Kornfeld H, Andrade BB, Gupta A. Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study. Eur Respir J. 2021 Oct 28:2100905. doi: 10.1183/13993003.00905-2021. Epub ahead of print. PMID: 34711538

  11. Arriaga MB, Araújo-Pereira M, Barreto-Duarte B, Nogueira B, Freire MVCNS, Queiroz ATL, Rodrigues MMS, Rocha MS, Souza AB, Spener-Gomes R, Carvalho ACC, Figueiredo MC, Turner MM, Durovni B, Lapa-E-Silva JR, Kritski AL, Cavalcante S, Rolla VC, Cordeiro-Santos M, Sterling TR, Andrade BB; RePORT Brazil consortium. The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes: A Multi-center Prospective Cohort Study. J Infect Dis. 2021 Oct 15:jiab427. doi: 10.1093/infdis/jiab427. Epub ahead of print. PMID: 34651642

  12. Tibúrcio R, Barreto-Duarte B, Naredren G, Queiroz ATL, Anbalagan S, Nayak K, Ravichandran N, Subramani R, Antonelli LRV, Satagopan K, Anbalagan K, Porter BO, Sher A, Swaminathan S, Sereti I, Andrade BB. Dynamics of T-Lymphocyte Activation Related to Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in Persons With Advanced HIV. Front Immunol. 2021 Oct 7;12:757843. doi: 10.3389/fimmu.2021.757843. PMID: 34691079; PMCID: PMC8529328

  13. Souza AB, Arriaga MB, Amorim G, Araújo-Pereira M, Nogueira BMF, Queiroz ATL, Figueiredo MC, Rocha MS, Benjamin A, Moreira ASR, Oliveira JG, Rolla V, Durovni B, Lapa E Silva JR, Kritski AL, Cavalcante S, Sterling T, Andrade BB, Cordeiro-Santos M; RePORT Brazil consortium. Determinants of losses in the latent tuberculosis infection cascade of care in Brazil. BMJ Glob Health. 2021 Sep;6(9):e005969. doi: 10.1136/bmjgh-2021-005969. PMID: 34518204

  14. Churchyard G, Cárdenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, Martinson N, Yimer G, Wang SH, Garcia-Basteiro AL, Nguenha D, Masilela L, Waggie Z, van den Hof S, Charalambous S, Cobelens F, Chaisson RE, Grant AD, Fielding KL; WHIP3TB Study Team*. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial. Ann Intern Med. 2021 Aug 24. doi: 10.7326/M20-7577. Epub ahead of print. PMID: 34424730

  15. Bohrer AC, Castro E, Hu Z, Queiroz ATL, Tocheny CE, Assmann M, Sakai S, Nelson C, Baker PJ, Ma H, Wang L, Zilu W, du Bruyn E, Riou C, Kauffman KD; Tuberculosis Imaging Program, Moore IN, Del Nonno F, Petrone L, Goletti D, Martineau AR, Lowe DM, Cronan MR, Wilkinson RJ, Barry CE, Via LE, Barber DL, Klion AD, Andrade BB, Song Y, Wong KW, Mayer-Barber KD. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. J Exp Med. 2021 Oct 4;218(10):e20210469. doi: 10.1084/jem.20210469. Epub 2021 Aug 4. PMID: 34347010; PMCID: PMC8348215

  16. Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Edward VA, Rassool M, Ahmed K, Fielding K, Ahidjo BA, Vangu MDT, Churchyard G. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021 Aug;9(8):897-908. doi: 10.1016/S2213-2600(20)30448-3. Epub 2021 Mar 16. Erratum in: Lancet Respir Med. 2021 Jun;9(6):e55. PMID: 33740465; PMCID: PMC8332197

  17. Haas DW, Mngqibisa R, Francis J, McIlleron H, Robinson JA, Kendall MA, Baker P, Mawlana S, Badal-Faesen S, Angira F, Omoz-Oarhe A, Samaneka WP, Denti P, Cohn SE; AIDS Clinical Trials Group A5338 Study Team. Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenet Genomics. 2021 Aug 6. doi: 10.1097/FPC.0000000000000448. Epub ahead of print. PMID: 34369424

  18. Bruyn ED, Fukutani KF, Rockwood N, Schutz C, Meintjes G, Arriaga MB, Cubillos-Angulo JM, Tibúrcio R, Sher A, Riou C, Wilkinson KA, Andrade BB, Wilkinson RJ. Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis. Lancet Microbe. 2021 Aug;2(8):e375-e385. doi: 10.1016/s2666-5247(21)00037-9. Epub 2021 May 18. PMID: 34386782; PMCID: PMC8357308

  19. Montepiedra G, Kim S, Weinberg A, Theron G, Sterling TR, LaCourse SM, Bradford S, Chakhtoura N, Jean-Philippe P, Evans S, Gupta A. Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. Clin Infect Dis. 2021 Aug 2;73(3):e587-e593. doi: 10.1093/cid/ciaa1674. PMID: 33146706; PMCID: PMC8326545

  20. Moodley N, Velen K, Saimen A, Zakhura N, Churchyard G, Charalambous S. Digital chest radiography enhances screening efficiency for pulmonary tuberculosis in primary health clinics, South Africa. Clin Infect Dis. 2021 Jul 27:ciab644. doi: 10.1093/cid/ciab644. Epub ahead of print. PMID: 34313729

  21. Barreto-Duarte B, Araújo-Pereira M, Nogueira BMF, Sobral L, Rodrigues MMS, Queiroz ATL, Rocha MS, Nascimento V, Souza AB, Cordeiro-Santos M, Kritski AL, Sterling TR, Arriaga MB, Andrade BB. Tuberculosis Burden and Determinants of Treatment Outcomes According to Age in Brazil: A Nationwide Study of 896,314 Cases Reported Between 2010 and 2019. Front Med (Lausanne). 2021 Jul 27;8:706689. doi: 10.3389/fmed.2021.706689. PMID: 34386510; PMCID: PMC8354381

  22. Simmons JD, Van PT, Stein CM, Chihota V, Ntshiqa T, Maenetje P, Peterson GJ, Reynolds A, Benchek P, Velen K, Fielding KL, Grant AD, Graustein AD, Nguyen FK, Seshadri C, Gottardo R, Mayanja-Kizza H, Wallis RS, Churchyard G, Boom WH, Hawn TR. Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-γ release assay conversion. J Clin Invest. 2021 Jul 15;131(14):e140073. doi: 10.1172/JCI140073. PMID: 34111032; PMCID: PMC8279582

  23. Carvalho ACC, Amorim G, Melo MGM, Silveira AKA, Vargas PHL, Moreira ASR, Rocha MS, Souza AB, Arriaga MB, Araújo-Pereira M, Figueiredo MC, Durovni B, Lapa-E-Silva JR, Cavalcante S, Rolla VC, Sterling TR, Cordeiro-Santos M, Andrade BB, Silva EC, Kritski AL; RePORT Brazil consortium. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Front Immunol. 2021 Jul 2;12:661934. doi: 10.3389/fimmu.2021.661934. PMID: 34276654; PMCID: PMC8284392.

  24. Peetluk LS, Rebeiro PF, Ridolfi FM, Andrade BB, Cordeiro-Santos M, Kritski A, Durovni B, Calvacante S, Figueiredo MC, Haas DW, Liu D, Rolla VC, Sterling TR; Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil network. A clinical prediction model for unsuccessful pulmonary tuberculosis treatment outcomes. Clin Infect Dis. 2021 Jul 2:ciab598. doi: 10.1093/cid/ciab598. Epub ahead of print. PMID: 34214166

  25. Costa DL, Amaral EP, Namasivayam S, Mittereder LR, Andrade BB, Sher A. Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work? Front Cell Infect Microbiol. 2021 Jun 21;11:672527. doi: 10.3389/fcimb.2021.672527. PMID: 34235093; PMCID: PMC8256258

  26. Cubillos-Angulo JM, Fernandes CD, Araújo DN, Carmo CA, Arriaga MB, Andrade BB. The influence of single nucleotide polymorphisms of NOD2 or CD14 on the risk of Mycobacterium tuberculosis diseases: a systematic review. Syst Rev. 2021 Jun 9;10(1):174. doi: 10.1186/s13643-021-01729-y. PMID: 34108050; PMCID: PMC8191055

  27. Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, Hadley K, Hikuam C, Musvosvi M, Bilek N, Erasmus M, Jaxa L, Raphela R, Nombida O, Kaskar M, Sumner T, White RG, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS-HR Study Team. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. Lancet Glob Health. 2021 Jun;9(6):e841-e853. doi: 10.1016/S2214-109X(21)00045-0. Epub 2021 Apr 13. PMID: 33862012; PMCID: PMC8131200.

  28. Krishnan S, Queiroz ATL, Gupta A, Gupte N, Bisson GP, Kumwenda J, Naidoo K, Mohapi L, Mave V, Mngqibisa R, Lama JR, Hosseinipour MC, Andrade BB, Karakousis PC. Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV. Front Immunol. 2021 Jun 8;12:676980. doi: 10.3389/fimmu.2021.676980. PMID: 34168648; PMCID: PMC8217878

  29. Shivakoti R, Newman JW, Hanna LE, Queiroz ATL, Borkowski K, Gupte AN, Paradkar M, Satyamurthi P, Kulkarni V, Selva M, Pradhan N, Shivakumar SVBY, Natarajan S, Karunaianantham R, Gupte N, Thiruvengadam K, Fiehn O, Bharadwaj R, Kagal A, Gaikwad S, Sangle S, Golub JE, Andrade BB, Mave V, Gupta A, Padmapriyadarsini C. Host Lipidome and Tuberculosis Treatment Failure. Eur Respir J. 2021 Jun 17:2004532. doi: 10.1183/13993003.04532-2020. Epub ahead of print. PMID: 34375300

  30. Ley SD, Pillay S, Streicher EM, van der Heijden YF, Sirgel F, Derendinger B, de Kock M, Gagneux S, Warren RM, Theron G, de Vos M. Melting the eis: Nondetection of Kanamycin Resistance Markers by Routine Diagnostic Tests and Identification of New eis Promoter Variants. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0250220. doi: 10.1128/AAC.02502-20. Epub 2021 Jun 17. PMID: 33903113; PMCID: PMC8218670

  31. Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, Hadley K, Hikuam C, Musvosvi M, Bilek N, Erasmus M, Jaxa L, Raphela R, Nombida O, Kaskar M, Sumner T, White RG, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS-HR Study Team. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. Lancet Glob Health. 2021 Jun;9(6):e841-e853. doi: 10.1016/S2214-109X(21)00045-0. Epub 2021 Apr 13. PMID: 33862012; PMCID: PMC8131200

  32. Maruri F, Guo Y, Blackman A, van der Heijden YF, Rebeiro PF, Sterling TR. Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance. Clin Infect Dis. 2021 Jun 1;72(11):1910-1918. doi: 10.1093/cid/ciaa496. PMID: 32348473; PMCID: PMC8315129

  33. Arriaga MB, Rocha MS, Nogueira B, Nascimento V, Araújo-Pereira M, Souza AB, Andrade AMS, Costa AG, Gomes-Silva A, Silva EC, Figueiredo MC, Turner MM, Durovni B, Lapa-E-Silva JR, Kritski AL, Cavalcante S, Rolla VC, Cordeiro-Santos M, Sterling TR, Andrade BB; RePORT Brazil consortium. The Effect of Diabetes and Prediabetes on Mycobacterium tuberculosis Transmission to Close Contacts. J Infect Dis. 2021 May 19:jiab264. doi: 10.1093/infdis/jiab264. Epub ahead of print. PMID: 34008010

  34. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. PMID: 33951360; PMCID: PMC8282329

  35. Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T, Haas DW, Browning R, Chakhtoura N, Montepiedra G, Aaron L, McCarthy K, Bradford S, Vhembo T, Stranix-Chibanda L, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Nevrekhar N, Rouzier V, Kabugho E, Mutambanengwe M, Chanaiwa V, Nyati M, Mhembere T, Tongprasert F, Hesseling A, Shin K, Zimmer B, Costello D, Jean-Philippe P, Sterling TR, Theron G, Weinberg A, Gupta A, Denti P; IMPAACT P1078 (TB APPRISE) Study Group Team. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clin Pharmacol Ther. 2021 Apr;109(4):1034-1044. doi: 10.1002/cpt.2044. Epub 2020 Oct 16. PMID: 32909316

  36. Vinhaes CL, Sheikh V, Oliveira-de-Souza D, Wang J, Rupert A, Roby G, Arriaga MB, Fukutani KF, Sawe F, Shaffer D, Ananworanich J, Phanuphak N, Andrade BB, Sereti I. An Inflammatory Composite Score Predicts Mycobacterial Immune Reconstitution Inflammatory Syndrome in People with Advanced HIV: A Prospective International Cohort Study. J Infect Dis. 2021 Apr 8;223(7):1275-1283. doi: 10.1093/infdis/jiaa484. PMID: 32761193; PMCID: PMC8030712

  37. Oleaga-Quintas C, de Oliveira-Júnior EB, Rosain J, Rapaport F, Deswarte C, Guérin A, Sajjath SM, Zhou YJ, Marot S, Lozano C, Branco L, Fernández-Hidalgo N, Lew DB, Brunel AS, Thomas C, Launay E, Arias AA, Cuffel A, Monjo VC, Neehus AL, Marques L, Roynard M, Moncada-Vélez M, Gerçeker B, Colobran R, Vigué MG, Lopez-Herrera G, Berron-Ruiz L, Méndez NHS, O'Farrill Romanillos P, Le Voyer T, Puel A, Bellanné-Chantelot C, Ramirez KA, Lorenzo-Diaz L, Alejo NR, de Diego RP, Condino-Neto A, Mellouli F, Rodriguez-Gallego C, Witte T, Restrepo JF, Jobim M, Boisson-Dupuis S, Jeziorski E, Fieschi C, Vogt G, Donadieu J, Pasquet M, Vasconcelos J, Ardeniz FO, Martínez-Gallo M, Campos RA, Jobim LF, Martínez-Barricarte R, Liu K, Cobat A, Abel L, Casanova JL, Bustamante J. Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance. J Clin Immunol. 2021 Apr;41(3):639-657. doi: 10.1007/s10875-020-00930-3. Epub 2021 Jan 8. PMID: 33417088

  38. Baliashvili D, Gandhi NR, Kim S, Hughes M, Mave V, Mendoza-Ticona A, Gonzales P, Kim N, Selvamuthu P, Badal-Faesen S, Upton C, Naini L, Smith E, Gupta A, Churchyard G, Swindells S, Hesseling A, Shah NS. Resistance to Mycobacterium tuberculosis infection among household contacts: a multinational study. Clin Infect Dis. 2021 Mar 27:ciab269. doi: 10.1093/cid/ciab269. Epub ahead of print. PMID: 33772550

  39. Manesen R, Mekler KA, Molobi TR, Tyiki AA, Madlavu MJ, Velen K, Charalambous S, van der Heijden YF. Data quality assessment of a South African electronic registry for drug-resistant TB, 2015-2016. Public Health Action. 2021 Mar 21;11(1):33-39. doi: 10.5588/pha.20.0031. PMID: 33777719; PMCID: PMC7987250

  40. Spener-Gomes R, Costa AG, de Melo HF, de Souza AB, Beraldi-Magalhães F, Jesus JS, Arriaga MB, Kritski A, Safe I, Andrade BB, Trajman A, Cordeiro-Santos M. Examination of respiratory specimens improves microbiological diagnosis of patients with presumptive extrapulmonary tuberculosis. Int J Infect Dis. 2021 Mar 12:S1201-9712(21)00240-X. doi: 10.1016/j.ijid.2021.03.022. Epub ahead of print. PMID: 33722683

  41. Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, Mendelsohn SC, Hadley K, Hikuam C, Kaskar M, Musvosvi M, Bilek N, Self S, Sumner T, White RG, Erasmus M, Jaxa L, Raphela R, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M; CORTIS-01 Study Team. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis. 2021 Mar;21(3):354-365. doi: 10.1016/S1473-3099(20)30914-2. Epub 2021 Jan 25. PMID: 33508224; PMCID: PMC7907670

  42. Peetluk LS, Ridolfi FM, Rebeiro PF, Liu D, Rolla VC, Sterling TR. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open. 2021 Mar 2;11(3):e044687. doi: 10.1136/bmjopen-2020-044687. PMID: 33653759; PMCID: PMC7929865

  43. Demers AM, Kim S, McCallum S, Eisenach K, Hughes M, Naini L, Mendoza-Ticona A, Pradhan N, Narunsky K, Poongulali S, Badal-Faesen S, Upton C, Smith E, Shah NS, Churchyard G, Gupta A, Hesseling A, Swindells S; ACTG A5300/IMPAACT I2003 PHOENIx Feasibility study team. Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial. BMC Infect Dis. 2021 Feb 24;21(1):205. doi: 10.1186/s12879-021-05884-4. PMID: 33627075; PMCID: PMC7903693

  44. Kulkarni V, Queiroz ATL, Sangle S, Kagal A, Salvi S, Gupta A, Ellner J, Kadam D, Rolla VC, Andrade BB, Salgame P, Mave V. A Two-Gene Signature for Tuberculosis Diagnosis in Persons With Advanced HIV. Front Immunol. 2021 Feb 22;12:631165. doi: 10.3389/fimmu.2021.631165. PMID: 33692804; PMCID: PMC7937880

  45. van der Horst M , Karamchand L , Bauer WS , Nel AJM , Blackburn JM , Wright DW . The cyanobacterial lectin, microvirin-N, enhances the specificity and sensitivity of lipoarabinomannan-based TB diagnostic tests. Analyst. 2021 Feb 21;146(4):1207-1215. doi: 10.1039/d0an01725f. Epub 2020 Dec 24. PMID: 33367346

  46. Amaral EP, Vinhaes CL, Oliveira-de-Souza D, Nogueira B, Akrami KM, Andrade BB. The Interplay Between Systemic Inflammation, Oxidative Stress, and Tissue Remodeling in Tuberculosis. Antioxid Redox Signal. 2021 Feb 20;34(6):471-485. doi: 10.1089/ars.2020.8124. Epub 2020 Jun 19. PMID: 32559410

  47. Blackman A, Morrison B, Maruri F, van der Heijden Y, Nochowicz CH, Guo Y, Scholz M, Rustad T, Sherman DR, Sterling TR. Re-evaluation of a novel resistance mutation in eccC5 of the ESX-5 secretion system in ofloxacin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 2021 Feb 11;76(3):820-822. doi: 10.1093/jac/dkaa507. PMID: 33367727; PMCID: PMC7879138

  48. Safe IP, Amaral EP, Araújo-Pereira M, Lacerda MVG, Printes VS, Souza AB, Beraldi-Magalhães F, Monteiro WM, Sampaio VS, Barreto-Duarte B, Andrade AMS, Spener-Gomes R, Costa AG, Cordeiro-Santos M, Andrade BB. Adjunct N-Acetylcysteine Treatment in Hospitalized Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood: Results From the RIPENACTB Study Trial. Front Immunol. 2021 Feb 4;11:602589. doi: 10.3389/fimmu.2020.602589. PMID: 33613521; PMCID: PMC7889506

  49. Haas DW, Podany AT, Bao Y, Swindells S, Chaisson RE, Mwelase N, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Baker P, Fletcher CV. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenet Genomics. 2021 Jan;31(1):17-27. doi: 10.1097/FPC.0000000000000417. PMID: 32815870; PMCID: PMC7655626

  50. Naik S, Alexander M, Kumar P, Kulkarni V, Deshpande P, Yadana S, Leu CS, Araújo-Pereira M, Andrade BB, Bhosale R, Babu S, Gupta A, Mathad JS, Shivakoti R. Systemic Inflammation in Pregnant Women With Latent Tuberculosis Infection. Front Immunol. 2021 Jan 27;11:587617. doi: 10.3389/fimmu.2020.587617. PMID: 33584652; PMCID: PMC7873478

  51. Gupte AN, Selvaraju S, Gaikwad S, Mave V, Kumar P, Babu S, Andrade BB, Checkley W, Bollinger R, Gupta A. Higher interleukin-6 levels and changes in transforming growth factor-β are associated with lung impairment in pulmonary tuberculosis. ERJ Open Res. 2021 Jan 18;7(1):00390-2020. doi: 10.1183/23120541.00390-2020. PMID: 33532468; PMCID: PMC7836581

  52. Costa DL, Amaral EP, Namasivayam S, Mittereder LR, Fisher L, Bonfim CC, Sardinha-Silva A, Thompson RW, Hieny SE, Andrade BB, Sher A. Heme oxygenase-1 inhibition promotes IFNγ- and NOS2-mediated control of Mycobacterium tuberculosis infection. Mucosal Immunol. 2021 Jan;14(1):253-266. doi: 10.1038/s41385-020-00342-x. Epub 2020 Aug 29. PMID: 32862202; PMCID: PMC7796944

  53. Auld SC, Kornfeld H, Maenetje P, Mlotshwa M, Chase W, Vangu MD, Torigian DA, Wallis RS, Churchyard G, Bisson GP. Pulmonary restriction predicts long-term pulmonary impairment in people with HIV and tuberculosis. BMC Pulm Med. 2021 Jan 7;21(1):19. doi: 10.1186/s12890-020-01368-4. PMID: 33413293; PMCID: PMC7791797

  54. Huaman MA, De Cecco CN, Bittencourt MS, Ticona E, Kityo C, Ballena I, Nalukwago S, Nazzinda R, Ticona C, Azañero R, Zhang B, Farquhar C, Hawn TR, Sterling TR, Fichtenbaum CJ, Longenecker CT. Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. Clin Infect Dis. 2021 Jan 3:ciaa1934. doi: 10.1093/cid/ciaa1934. Epub ahead of print. PMID: 33388766

 

2020

  1. Barreto-Duarte B, Sterling TR, Fiske CT, Almeida A, Nochowicz CH, Smith RM, Barnett L, Warren C, Blackman A, Lapa E Silva JR, Andrade BB, Kalams SA. Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis. Front Immunol. 2020 Dec 17;11:605338. doi: 10.3389/fimmu.2020.605338. PMID: 33391271; PMCID: PMC7774017

  2. Manabe YC, Andrade BB, Gupte N, Leong S, Kintali M, Matoga M, Riviere C, Samaneka W, Lama JR, Naidoo K, Zhao Y, Johnson WE, Ellner JJ, Hosseinipour MC, Bisson GP, Salgame P, Gupta A. A Parsimonious Host Inflammatory Biomarker Signature Predicts Incident Tuberculosis and Mortality in Advanced Human Immunodeficiency Virus. Clin Infect Dis. 2020 Dec 17;71(10):2645-2654. doi: 10.1093/cid/ciz1147. PMID: 31761933; PMCID: PMC7744990

  3. Arriaga MB, Amorim G, Queiroz ATL, Rodrigues MMS, Araújo-Pereira M, Nogueira BMF, Souza AB, Rocha MS, Benjamin A, Moreira ASR, de Oliveira JG, Figueiredo MC, Turner MM, Alves K, Durovni B, Lapa-E-Silva JR, Kritski AL, Cavalcante S, Rolla VC, Cordeiro-Santos M, Sterling TR, Andrade BB; RePORT Brazil consortium. Novel Stepwise Approach to Assess Representativeness of a Large Multicenter Observational Cohort of Tuberculosis Patients: The Example of RePORT Brazil. Int J Infect Dis. 2020 Nov 13:S1201-9712(20)32452-8. doi: 10.1016/j.ijid.2020.11.140. Epub ahead of print. PMID: 33197582; PMCID: PMC7959330

  4. Dutta NK, Tornheim JA, Fukutani KF, Paradkar M, Tiburcio RT, Kinikar A, Valvi C, Kulkarni V, Pradhan N, Shivakumar SVBY, Kagal A, Gupte A, Gupte N, Mave V, Gupta A, Andrade BB, Karakousis PC. Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children. Sci Rep. 2020 Nov 11;10(1):19527. doi: 10.1038/s41598-020-75513-8. PMID: 33177551; PMCID: PMC7658223

  5. Silveira-Mattos PS, Barreto-Duarte B, Vasconcelos B, Fukutani KF, Vinhaes CL, Oliveira-De-Souza D, Ibegbu CC, Figueiredo MC, Sterling TR, Rengarajan J, Andrade BB. Differential Expression of Activation Markers by Mycobacterium tuberculosis-specific CD4+ T Cell Distinguishes Extrapulmonary From Pulmonary Tuberculosis and Latent Infection. Clin Infect Dis. 2020 Nov 5;71(8):1905-1911. doi: 10.1093/cid/ciz1070. PMID: 31665254

  6. Montepiedra G, Kim S, Weinberg A, Theron G, Sterling TR, LaCourse SM, Bradford S, Chakhtoura N, Jean-Philippe P, Evans S, Gupta A. Using a composite maternal-infant outcome measure in tuberculosis prevention studies among pregnant women. Clin Infect Dis. 2020 Nov 4:ciaa1674. doi: 10.1093/cid/ciaa1674. Epub ahead of print. PMID: 33146706

  7. Reichler MR, Khan A, Yuan Y, Chen B, McAuley J, Mangura B, Sterling TR; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection. Clin Infect Dis. 2020 Oct 23;71(7):1627-1634. doi: 10.1093/cid/ciz1044. PMID: 32044987

  8. Sterling TR, Lin PL. Treatment of latent M. tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis. J Clin Invest. 2020 Oct 1;130(10):5102-5104. doi: 10.1172/JCI137294. PMID: 32831291; PMCID: PMC7524504

  9. Merrikh H, Kohli RM. Targeting evolution to inhibit antibiotic resistance. FEBS J. 2020 Oct;287(20):4341-4353. doi: 10.1111/febs.15370. Epub 2020 Jun 8. PMID: 32434280; PMCID: PMC7578009

  10. Demitto FO, Araújo-Pereira M, Schmaltz CA, Sant'Anna FM, Arriaga MB, Andrade BB, Rolla VC. Impact of Persistent Anemia on Systemic Inflammation and Tuberculosis Outcomes in Persons Living With HIV. Front Immunol. 2020 Sep 24;11:588405. doi: 10.3389/fimmu.2020.588405. PMID: 33072136; PMCID: PMC7541849

  11. Narendran G, Jyotheeswaran K, Senguttuvan T, Vinhaes CL, Santhanakrishnan RK, Manoharan T, Selvaraj A, Chandrasekaran P, Menon PA, Bhavani KP, Reddy D, Narayanan R, Subramanyam B, Sathyavelu S, Krishnaraja R, Kalirajan P, Angamuthu D, Susaimuthu SM, Ganesan RRK, Tripathy SP, Swaminathan S, Andrade BB. Characteristics of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and its influence on tuberculosis treatment outcomes in persons living with HIV. Int J Infect Dis. 2020 Sep;98:261-267. doi: 10.1016/j.ijid.2020.06.097. Epub 2020 Jul 2. PMID: 32623087

  12. Ndlovu LN, Peetluk L, Moodley S, Nhamoyebonde S, Ngoepe AT, Mazibuko M, Khan K, Karim F, Pym AS, Maruri F, Moosa MS, van der Heijden YF, Sterling TR, Leslie A. Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection. Front Immunol. 2020 Aug 28;11:1872. doi: 10.3389/fimmu.2020.01872. PMID: 32983107; PMCID: PMC7485225

  13. Manful A, Waller L, Katz B, Cummins J, Warkentin J, Reagon B, Shaw-Kaikai J, Zhu Y, van der Heijden YF. Gaps in the care cascade for screening and treatment of refugees with tuberculosis infection in Middle Tennessee: a retrospective cohort study. BMC Infect Dis. 2020 Aug 10;20(1):592. doi: 10.1186/s12879-020-05311-0. PMID: 32778060; PMCID: PMC7418421

  14. Pettit AC, Stout JE, Belknap R, Benson CA, Séraphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS; Tuberculosis Epidemiologic Studies Consortium (TBESC). Optimal testing choice and diagnostic strategies for latent tuberculosis infection among U.S.-born people living with HIV. Clin Infect Dis. 2020 Aug 6:ciaa1135. doi: 10.1093/cid/ciaa1135. Epub ahead of print. PMID: 32761083

  15. Reichler MR, Hirsch C, Yuan Y, Khan A, Dorman SE, Schluger N, Sterling TR; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. BMC Infect Dis. 2020 Jul 31;20(1):553. doi: 10.1186/s12879-020-05185-2. PMID: 32736606; PMCID: PMC7394686

  16. Weinberg A, Aaron L, Montepiedra G, Sterling TR, Browning R, Mmbaga B, Vhembo T, Naik S, Kabugho E, Masheto G, Pahwa S, Mathad JS, LaCourse SM, McCarthy K, Bradford S, Theron G, Costello D, Zimmer B, Pierre MF, Gausi K, Denti P, Haas DW, Gupta A; IMPAACT P1078 study team. Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV. Clin Infect Dis. 2020 Jul 28:ciaa1083. doi: 10.1093/cid/ciaa1083. Epub ahead of print. PMID: 32720695.

  17. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. Am J Respir Crit Care Med. 2020 Jul 15;202(2):305-306. doi: 10.1164/rccm.202003-0855LE. PMID: 32282235; PMCID: PMC7365358

  18. Oliveira-de-Souza D, Vinhaes CL, Arriaga MB, Kumar NP, Queiroz ATL, Fukutani KF, Babu S, Andrade BB. Aging increases the systemic molecular degree of inflammatory perturbation in patients with tuberculosis. Sci Rep. 2020 Jul 9;10(1):11358. doi: 10.1038/s41598-020-68255-0. PMID: 32647178; PMCID: PMC7347549

  19. Safe IP, Lacerda MVG, Printes VS, Praia Marins AF, Rebelo Rabelo AL, Costa AA, Tavares MA, Jesus JS, Souza AB, Beraldi-Magalhães F, Neves CP, Monteiro WM, Sampaio VS, Amaral EP, Gomes RS, Andrade BB, Cordeiro-Santos M. Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study). PLoS One. 2020 Jun 26;15(6):e0235381. doi: 10.1371/journal.pone.0235381. PMID: 32589648; PMCID: PMC7319340

  20. Koenig SP, Kim A, Shepherd BE, Cesar C, Veloso V, Cortes CP, Padgett D, Crabtree-Ramírez B, Gotuzzo E, McGowan CC, Sterling TR, Pape JW. Increased Mortality After Tuberculosis Treatment Completion in Persons Living With Human Immunodeficiency Virus in Latin America. Clin Infect Dis. 2020 Jun 24;71(1):215-217. doi: 10.1093/cid/ciz1032. PMID: 31629369; PMCID: PMC7312222

  21. Rebeiro PF, Cohen MJ, Ewing HM, Figueiredo MC, Peetluk LS, Andrade KB, Eakin M, Zechmeister EJ, Sterling TR. Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies. BMC Public Health. 2020 Jun 9;20(1):897. doi: 10.1186/s12889-020-09053-1. PMID: 32517671; PMCID: PMC7285569

  22. Kerner G, Rosain J, Guérin A, Al-Khabaz A, Oleaga-Quintas C, Rapaport F, Massaad MJ, Ding JY, Khan T, Ali FA, Rahman M, Deswarte C, Martinez-Barricarte R, Geha RS, Jeanne-Julien V, Garcia D, Chi CY, Yang R, Roynard M, Fleckenstein B, Rozenberg F, Boisson-Dupuis S, Ku CL, Seeleuthner Y, Béziat V, Marr N, Abel L, Al-Herz W, Casanova JL, Bustamante J. Inherited human IFN-γ deficiency underlies mycobacterial disease. J Clin Invest. 2020 Jun 1;130(6):3158-3171. doi: 10.1172/JCI135460. PMID: 32163377; PMCID: PMC7260033.

  23. Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM. Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection. J Clin Microbiol. 2020 May 26;58(6):e00393-20. doi: 10.1128/JCM.00393-20. PMID: 32245831; PMCID: PMC7269374

  24. Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, Malherbe ST, Darboe F, Erasmus M, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Winter J, Murphy M, Wood R, Morrow C, Van Rhijn I, Moody B, Murray M, Andrade BB, Sterling TR, Sutherland J, Naidoo K, Padayatchi N, Walzl G, Hatherill M, Zak D, Scriba TJ; Adolescent Cohort Study team; GC6-74 Consortium; SATVI Clinical and Laboratory Team; ScreenTB Consortium; AE-TBC Consortium; RePORT Brazil Team; Peruvian Household Contacts Cohort Team; CAPRISA IMPRESS team. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Sci Rep. 2020 May 25;10(1):8629. doi: 10.1038/s41598-020-65043-8. PMID: 32451443; PMCID: PMC7248089

  25. Herricks T, Donczew M, Mast FD, Rustad T, Morrison R, Sterling TR, Sherman DR, Aitchison JD. ODELAM, rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis. Elife. 2020 May 13;9:e56613. doi: 10.7554/eLife.56613. PMID: 32401195; PMCID: PMC7263823

  26. Maruri F, Guo Y, Blackman A, van der Heijden YF, Rebeiro PF, Sterling TR. Resistance-conferring mutations on whole-genome sequencing of fluoroquinolone-resistant and -susceptible M. tuberculosis isolates: a proposed threshold for identifying resistance. Clin Infect Dis. 2020 Apr 29:ciaa496. doi: 10.1093/cid/ciaa496. Epub ahead of print. PMID: 32348473

  27. Tornheim JA, Madugundu AK, Paradkar M, Fukutani KF, Queiroz ATL, Gupte N, Gupte AN, Kinikar A, Kulkarni V, Balasubramanian U, Sreenivasamurthy S, Raja R, Pradhan N, Shivakumar SVBY, Valvi C, Hanna LE, Andrade BB, Mave V, Pandey A, Gupta A; CTRIUMPh RePORT India Study Team. Transcriptomic Profiles of Confirmed Pediatric Tuberculosis Patients and Household Contacts Identifies Active Tuberculosis, Infection, and Treatment Response Among Indian Children. J Infect Dis. 2020 Apr 27;221(10):1647-1658. doi: 10.1093/infdis/jiz639. PMID: 31796955; PMCID: PMC7184902

  28. Reichler MR, Khan A, Sterling TR, Zhao H, Chen B, Yuan Y, Moran J, McAuley J, Mangura B; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons With Infectious Tuberculosis. Clin Infect Dis. 2020 Apr 10;70(8):1562-1572. doi: 10.1093/cid/ciz438. PMID: 31127813; PMCID: PMC7011200

  29. Peetluk LS, Rebeiro PF, Cordeiro-Santos M, Kritski A, Andrade BB, Durovni B, Calvacante S, Arriaga MB, Turner MM, Figueiredo MC, Rolla VC, Sterling TR; Lack of weight gain during the first two months of treatment and HIV independently predict unsuccessful treatment outcomes in tuberculosis. Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil network. J Infect Dis. 2020 Apr 7;221(9):1416-1424. doi: 10.1093/infdis/jiz595. PMID: 31724035; PMCID: PMC7137883

  30. Araújo NCN, Cruz CMS, Arriaga MB, Cubillos-Angulo JM, Rocha MS, Silveira-Mattos PS, Matos GM, Marques IMB, Espirito Santo ICP, Almeida LL, Andrade CM, Souza LA, Netto EM, Andrade BB. Determinants of losses in the latent tuberculosis cascade of care in Brazil: A retrospective cohort study. Int J Infect Dis. 2020 Apr;93:277-283. doi: 10.1016/j.ijid.2020.02.015. Epub 2020 Feb 17. PMID: 32081776; PMCID: PMC7245517.

  31. Shivakoti R, Dalli J, Kadam D, Gaikwad S, Barthwal M, Colas RA, Mazzacuva F, Lokhande R, Dharmshale S, Bharadwaj R, Kagal A, Pradhan N, Deshmukh S, Atre S, Sahasrabudhe T, Kakrani A, Kulkarni V, Raskar S, Suryavanshi N, Chon S, Gupte A, Gupta A, Gupte N, Arriaga MB, Fukutani KF, Andrade BB, Golub JE, Mave V. Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes. Prostaglandins Other Lipid Mediat. 2020 Apr;147:106398. doi: 10.1016/j.prostaglandins.2019.106398. Epub 2019 Nov 11. PMID: 31726221; PMCID: PMC7067657

  32. Nacarapa E, Muchiri E, Moon TD, Charalambous S, Verdu ME, Ramos JM, Valverde EJ. Effect of Xpert MTB/RIF testing introduction and favorable outcome predictors for tuberculosis treatment among HIV infected adults in rural southern Mozambique. A retrospective cohort study. PLoS One. 2020 Mar 9;15(3):e0229995. doi: 10.1371/journal.pone.0229995. PMID: 32150595; PMCID: PMC7062249.

  33. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med. 2020 Mar 1;201(5):598-605. doi: 10.1164/rccm.201908-1606OC. PMID: 31711306

  34. Cubillos-Angulo JM, Arriaga MB, Melo MGM, Silva EC, Alvarado-Arnez LE, de Almeida AS, Moraes MO, Moreira ASR, Lapa E Silva JR, Fukutani KF, Sterling TR, Hawn TR, Kritski AL, Oliveira MM, Andrade BB. Polymorphisms in interferon pathway genes and risk of Mycobacterium tuberculosis infection in contacts of tuberculosis cases in Brazil. Int J Infect Dis. 2020 Mar;92:21-28. doi: 10.1016/j.ijid.2019.12.013. Epub 2019 Dec 13. PMID: 31843671; PMCID: PMC7197195

  35. Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020 Mar;90:105938. doi: 10.1016/j.cct.2020.105938. Epub 2020 Jan 22. PMID: 31981713; PMCID: PMC7307310

  36. Barreda NN, Arriaga MB, Aliaga JG, Lopez K, Sanabria OM, Carmo TA, Fróes Neto JF, Lecca L, Andrade BB, Calderon RI. Severe pulmonary radiological manifestations are associated with a distinct biochemical profile in blood of tuberculosis patients with dysglycemia. BMC Infect Dis. 2020 Feb 14;20(1):139. doi: 10.1186/s12879-020-4843-0. PMID: 32059707; PMCID: PMC7023734

  37. Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 Feb 14;69(1):1-11. doi: 10.15585/mmwr.rr6901a1. PMID: 32053584; PMCID: PMC7041302

  38. Humphrey JM, Mpofu P, Pettit AC, Musick B, Carter EJ, Messou E, Marcy O, Crabtree-Ramirez B, Yotebieng M, Anastos K, Sterling TR, Yiannoutsos C, Diero L, Wools-Kaloustian K. Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium. Open Forum Infect Dis. 2020 Jan 10;7(1):ofaa006. doi: 10.1093/ofid/ofaa006. PMID: 32010735; PMCID: PMC6984675

 

2019

  1. Arriaga MB, Torres NMC, Araujo NCN, Caldas SCC, Andrade BB, Netto EM. Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study. PLoS One. 2019 Dec 26;14(12):e0227101. doi: 10.1371/journal.pone.0227101. PMID: 31877199; PMCID: PMC6932797

  2. Pettit AC, Jenkins CA, Blevins Peratikos M, Yotebieng M, Diero L, Do CD, Ross J, Veloso VG, Hawerlander D, Marcy O, Shepherd BE, Fenner L, Sterling TR; International Epidemiology Databases to Evaluate AIDS (IeDEA) Consortium. Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in low- and middle-income countries. J Int AIDS Soc. 2019 Dec;22(12):e25423. doi: 10.1002/jia2.25423. PMID: 31814312; PMCID: PMC6900483

  3. Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med. 2019 Dec;40(4):839-848. doi: 10.1016/j.ccm.2019.07.008. PMID: 31731988; PMCID: PMC7043866

  4. Albuquerque VVS, Kumar NP, Fukutani KF, Vasconcelos B, Arriaga MB, Silveira-Mattos PS, Babu S, Andrade BB. Plasma levels of C-reactive protein, matrix metalloproteinase-7 and lipopolysaccharide-binding protein distinguish active pulmonary or extrapulmonary tuberculosis from uninfected controls in children. Cytokine. 2019 Nov;123:154773. doi: 10.1016/j.cyto.2019.154773. Epub 2019 Jul 9. PMID: 31299414

  5. Vinhaes CL, Oliveira-de-Souza D, Silveira-Mattos PS, Nogueira B, Shi R, Wei W, Yuan X, Zhang G, Cai Y, Barry CE 3rd, Via LE, Fukutani KF, Andrade BB, Mayer-Barber KD. Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study. Cytokine. 2019 Nov;123:154759. doi: 10.1016/j.cyto.2019.154759. Epub 2019 Jun 18. PMID: 31226436; PMCID: PMC6739167

  6. Gibson EG, Oviatt AA, Cacho M, Neuman KC, Chan PF, Osheroff N. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV. Biochemistry. 2019 Nov 5;58(44):4447-4455. doi: 10.1021/acs.biochem.9b00805. Epub 2019 Oct 28. PMID: 31617352; PMCID: PMC7450530

  7. Moon TD, Nacarapa E, Verdu ME, Macuácua S, Mugabe D, Gong W, Carlucci JG, Ramos JM, Valverde E. Tuberculosis Treatment Outcomes Among Children in Rural Southern Mozambique: A 12-year Retrospective Study. Pediatr Infect Dis J. 2019 Oct;38(10):999-1004. doi: 10.1097/INF.0000000000002435. PMID: 31568138; PMCID: PMC6776242

  8. Zürcher K, Ballif M, Kiertiburanakul S, Chenal H, Yotebieng M, Grinsztejn B, Michael D, Sterling TR, Ngonyani KM, Mandalakas AM, Egger M, Pettit AC, Fenner L; International Epidemiology Databases to Evaluate AIDS (IeDEA) consortium. Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low- and middle-income countries: a multicohort study. J Int AIDS Soc. 2019 Sep;22(9):e25392. doi: 10.1002/jia2.25392. PMID: 31507083; PMCID: PMC6737289

  9. van der Heijden YF, Hughes J, Dowdy DW, Streicher E, Chihota V, Jacobson KR, Warren R, Theron G. Overcoming limitations of tuberculosis information systems: researcher and clinician perspectives. Public Health Action. 2019 Sep 21;9(3):120-127. doi: 10.5588/pha.19.0014. PMID: 31803584; PMCID: PMC6827492

  10. Stout JE, Sterling TR, Horsburgh CR Jr. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Sep 12;381(11):e23. doi: 10.1056/NEJMc1908492. PMID: 31509689.

  11. Calderon RI, Arriaga MB, Lopez K, Barreda NN, Sanabria OM, Fróes Neto JF, Araújo DN, Lecca L, Andrade BB. High prevalence and heterogeneity of Dysglycemia in patients with tuberculosis from Peru: a prospective cohort study. BMC Infect Dis. 2019 Sep 11;19(1):799. doi: 10.1186/s12879-019-4416-2. PMID: 31510930; PMCID: PMC6737721

  12. Cubillos-Angulo JM, Arriaga MB, Silva EC, Müller BLA, Ramalho DMP, Fukutani KF, Miranda PFC, Moreira ASR, Ruffino-Netto A, Lapa E Silva JR, Sterling TR, Kritski AL, Oliveira MM, Andrade BB. Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study. Clin Infect Dis. 2019 Aug 30;69(6):1027-1035. doi: 10.1093/cid/ciy1001. PMID: 30481307; PMCID: PMC6735688

  13. Schutz C, Barr D, Andrade BB, Shey M, Ward A, Janssen S, Burton R, Wilkinson KA, Sossen B, Fukutani KF, Nicol M, Maartens G, Wilkinson RJ, Meintjes G. Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study. PLoS Med. 2019 Jul 5;16(7):e1002840. doi: 10.1371/journal.pmed.1002840. PMID: 31276515; PMCID: PMC6611568.

  14. Kumar NP, Fukutani KF, Shruthi BS, Alves T, Silveira-Mattos PS, Rocha MS, West K, Natarajan M, Viswanathan V, Babu S, Andrade BB, Kornfeld H. Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity. Elife. 2019 Jul 4;8:e46477. doi: 10.7554/eLife.46477. PMID: 31271354; PMCID: PMC6660216

  15. Narendran G, Oliveira-de-Souza D, Vinhaes CL, Akrami K, Fukutani KF, Banu K, Chandrasekaran P, Ravichandran N, Sereti I, Swaminathan S, Andrade BB. Multifocal tuberculosis-associated immune reconstitution inflammatory syndrome - a case report of a complicated scenario. BMC Infect Dis. 2019 Jun 17;19(1):529. doi: 10.1186/s12879-019-4182-1. PMID: 31208430; PMCID: PMC6580602

  16. Demitto FO, Schmaltz CAS, Sant'Anna FM, Arriaga MB, Andrade BB, Rolla VC. Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil. PLoS One. 2019 Jun 6;14(6):e0217014. doi: 10.1371/journal.pone.0217014. PMID: 31170171; PMCID: PMC6553696

  17. Oliveira-de-Souza D, Vinhaes CL, Arriaga MB, Kumar NP, Cubillos-Angulo JM, Shi R, Wei W, Yuan X, Zhang G, Cai Y, Barry CE 3rd, Via LE, Sher A, Babu S, Mayer-Barber KD, Nakaya HI, Fukutani KF, Andrade BB. Molecular degree of perturbation of plasma inflammatory markers associated with tuberculosis reveals distinct disease profiles between Indian and Chinese populations. Sci Rep. 2019 May 29;9(1):8002. doi: 10.1038/s41598-019-44513-8. PMID: 31142816; PMCID: PMC6541651

  18. Fiske CT, Blackman A, Maruri F, Rebeiro PF, Huaman M, Kator J, Scott Algood HM, Sterling TR. Increased vitamin D receptor expression from macrophages after stimulation with M. tuberculosis among persons who have recovered from extrapulmonary tuberculosis. BMC Infect Dis. 2019 Apr 30;19(1):366. doi: 10.1186/s12879-019-3958-7. PMID: 31039752; PMCID: PMC6492421

  19. Khan PY, Yates TA, Osman M, Warren RM, van der Heijden Y, Padayatchi N, Nardell EA, Moore D, Mathema B, Gandhi N, Eldholm V, Dheda K, Hesseling AC, Mizrahi V, Rustomjee R, Pym A. Transmission of drug-resistant tuberculosis in HIV-endemic settings. Lancet Infect Dis. 2019 Mar;19(3):e77-e88. Epub 2018 Dec 13. Review. Erratum in: Lancet Infect Dis. 2019 Mar 6. PMID: 30554996

  20. Crabtree-Ramírez B, Jenkins C, Jayathilake K, Carriquiry G, Veloso V, Padgett D, Gotuzzo E, Cortes C, Mejia F, McGowan CC, Duda S, Shepherd BE, Sterling TR. HIV-related tuberculosis: mortality risk in persons without vs. with culture-confirmed disease. Int J Tuberc Lung Dis. 2019 Mar 1;23(3):306-314. doi: 10.5588/ijtld.18.0111. PMID: 30871661; PMCID: PMC6537600

  21. Peters JS, Andrews JR, Hatherill M, Hermans S, Martinez L, Schurr E, van der Heijden Y, Wood R, Rustomjee R, Kana BD. Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. Lancet Infect Dis. 2019 Mar;19(3):e65-e76. doi: 10.1016/S1473-3099(18)30477-8. Epub 2018 Dec 13. PMID: 30554995; PMCID: PMC6401310

  22. Amaral EP, Costa DL, Namasivayam S, Riteau N, Kamenyeva O, Mittereder L, Mayer-Barber KD, Andrade BB, Sher A. A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis. J Exp Med. 2019 Mar 4;216(3):556-570. doi: 10.1084/jem.20181776. Epub 2019 Feb 20. PMID: 30787033; PMCID: PMC6400546

  23. Silveira-Mattos PS, Narendran G, Akrami K, Fukutani KF, Anbalagan S, Nayak K, Subramanyam S, Subramani R, Vinhaes CL, Souza DO, Antonelli LR, Satagopan K, Porter BO, Sher A, Swaminathan S, Sereti I, Andrade BB. Differential expression of CXCR3 and CCR6 on CD4+ T-lymphocytes with distinct memory phenotypes characterizes tuberculosis-associated immune reconstitution inflammatory syndrome. Sci Rep. 2019 Feb 6;9(1):1502. doi: 10.1038/s41598-018-37846-3. Erratum in: Sci Rep. 2019 May 24;9(1):8036. PMID: 30728405; PMCID: PMC6365576

  24. Gil-Santana L, Cruz LAB, Arriaga MB, Miranda PFC, Fukutani KF, Silveira-Mattos PS, Silva EC, Oliveira MG, Mesquita EDD, Rauwerdink A, Cobelens F, Oliveira MM, Kritski A, Andrade BB. Tuberculosis-associated anemia is linked to a distinct inflammatory profile that persists after initiation of antitubercular therapy. Sci Rep. 2019 Feb 4;9(1):1381. doi: 10.1038/s41598-018-37860-5. PMID: 30718725; PMCID: PMC6361962

  25. Ragheb MN, Thomason MK, Hsu C, Nugent P, Gage J, Samadpour AN, Kariisa A, Merrikh CN, Miller SI, Sherman DR, Merrikh H. Inhibiting the Evolution of Antibiotic Resistance. Mol Cell. 2019 Jan 3;73(1):157-165.e5. doi: 10.1016/j.molcel.2018.10.015. Epub 2018 Nov 15. PMID: 30449724; PMCID: PMC6320318.

 

2018

  1. van der Heijden YF, Abdullah F, Andrade BB, Andrews JR, Christopher DJ, Croda J, Ewing H, Haas DW, Hatherill M, Horsburgh CR Jr, Mave V, Nakaya HI, Rolla V, Srinivasan S, Sugiyono RI, Ugarte-Gil C, Hamilton C. Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting. Tuberculosis (Edinb). 2018 Dec;113:153-162. doi: 10.1016/j.tube.2018.09.009. Epub 2018 Oct 1. PMID: 30514497; PMCID: PMC6349374

  2. Pettit AC, Shepherd BE, Sterling TR. Treatment of drug-susceptible tuberculosis among people living with human immunodeficiency virus infection: an update. Curr Opin HIV AIDS. 2018 Nov;13(6):469-477. doi: 10.1097/COH.0000000000000506. PMID: 30222609; PMCID: PMC6389504

  3. Stout JE, Wu Y, Ho CS, Pettit AC, Feng PJ, Katz DJ, Ghosh S, Venkatappa T, Luo R; Tuberculosis Epidemiologic Studies Consortium. Evaluating latent tuberculosis infection diagnostics using latent class analysis. Thorax. 2018 Nov;73(11):1062-1070. doi: 10.1136/thoraxjnl-2018-211715. Epub 2018 Jul 7. PMID: 29982223; PMCID: PMC6494673

  4. Huaman MA, Henson D, Rondan PL, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, Ticona C, Abarca S, Heredia P, Aguirre A, Sterling TR, Garvy BA, Fichtenbaum CJ. Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru. PLoS One. 2018 Sep 13;13(9):e0202191. PMID: 30212453, PMCID: PMC6136705

  5. Reichler MR, Khan A, Sterling TR, Zhao H, Moran J, McAuley J, Bessler P, Mangura B; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis. J Infect Dis. 2018 Aug 14;218(6):1000-1008. doi: 10.1093/infdis/jiy265. PMID: 29767733; PMCID: PMC6534268

  6. Gibson EG, Blower TR, Cacho M, Bax B, Berger JM, Osheroff N. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons. ACS Infect Dis. 2018 Aug 10;4(8):1211-1222. doi: 10.1021/acsinfecdis.8b00035. Epub 2018 May 17. PMID: 29746087; PMCID: PMC6309371.

  7. van der Heijden YF, Karim F, Chinappa T, Mufamadi G, Zako L, Shepherd BE, Maruri F, Moosa MS, Sterling TR, Pym AS. Older age at first tuberculosis diagnosis is associated with tuberculosis recurrence in HIV-negative persons. Int J Tuberc Lung Dis. 2018 Aug 1;22(8):871-877. PMID: 29991395, PMCID: PMC6064608

  8. Amaral EP, Riteau N, Moayeri M, Maier N, Mayer-Barber KD, Pereira RM, Lage SL, Kubler A, Bishai WR, D'Império-Lima MR, Sher A, Andrade BB. Lysosomal Cathepsin Release Is Required for NLRP3-Inflammasome Activation by Mycobacterium tuberculosis in Infected Macrophages. Front Immunol. 2018 Jun 21;9:1427. PMID: 29977244, PMCID: PMC6021483

  9. Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chaisson RE, Narita M, Machado ES, Lopez M, Sanchez J, Villarino ME, Sterling TR. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018 May;15(5):570-580. doi: 10.1513/AnnalsATS.201704-326OC. PMID: 29393655; PMCID: PMC6624829.

  10. Huaman MA, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, Rondan P, Henson D, Ticona C, Sterling TR, Fichtenbaum C, Garvy BA. The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction. Clin Infect Dis. 2018 Mar 5;66(6):886-892. PMID: 29069328, PMCID:PMC5850031

  11. Ramírez S, Mejía F, Rojas M, Seas C, Van der Stuyft P, Gotuzzo E, Otero L. HIV screening among newly diagnosed TB patients: a cross sectional study in Lima, Peru. BMC Infect Dis. 2018 Mar 20;18(1):136. PMID: 29558891, PMCID: PMC5861614

  12. Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, Chaturvedi N, Srinivasan S, Johnson DH, Bishai WR. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. Lancet Infect Dis. 2018 Mar;18(3):e64-e75. doi: 10.1016/S1473-3099(17)30623-0. Epub 2017 Oct 27. PMID: 29111156

  13. Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR; Antiretroviral Therapy Cohort Collaboration (ART-CC) investigators. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. J Int AIDS Soc. 2018 Jan;21(1). PMID: 29334197, PMCID: PMC5810321

  14. Hussain S, Hasnain J, Hussain Z, Badshah M, Siddique H, Fiske C, Pettit A. Type of Treatment Supporters in Successful Completion of Tuberculosis Treatment: A Retrospective Cohort Study in Pakistan. Open Infect Dis J. 2018;10:37-42. PMID: 30008966, PMCID: PMC6044441

  15. Grifoni A, Sidney J, Carpenter C, Phillips E, Mallal S, Scriba TJ, Sette A, Lindestam Arlehamn CS. Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester region of the Western Cape province of South Africa. Hum Immunol. 2018 Mar;79(3):143-144. PMID: 29398200.

2017

  1. Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017 Nov 21;167(10):689-697. doi: 10.7326/M17-1150. Epub 2017 Nov 7. PMID: 29114781; PMCID: PMC5766341

  2. Ashley RE, Blower TR, Berger JM, Osheroff N. Recognition of DNA Supercoil Geometry by Mycobacterium tuberculosis Gyrase. Biochemistry. 2017 Oct 10;56(40):5440-5448. Epub 2017 Sep 25. PMCID: PMC5637011

  3. Bourgi K, Fiske C, Sterling TR. Tuberculosis Meningitis. Curr Infect Dis Rep. 2017 Sep 11;19(11):39. doi: 10.1007/s11908-017-0595-4. PMID: 28895024

  4. Carlucci JG, Blevins Peratikos M, Kipp AM, Lindegren ML, Du QT, Renner L, Reubenson G, Ssali J, Yotebieng M, Mandalakas AM, Davies MA, Ballif M, Fenner L, Pettit AC; International Epidemiology Databases to Evaluate AIDS (IeDEA) Network. Tuberculosis Treatment Outcomes Among HIV/TB-Coinfected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network. J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):156-163. doi: 10.1097/QAI.0000000000001335. PMID: 28234689; PMCID: PMC5429189

  5. van der Heijden YF, Karim F, Mufamadi G, Zako L, Chinappa T, Shepherd BE, Maruri F, Moosa MS, Sterling TR, Pym AS. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. Int J Tuberc Lung Dis. 2017 Jun 1;21(6):670-676. PMCID: PMC5536436

  6. Prada-Medina CA, Fukutani KF, Pavan Kumar N, Gil-Santana L, Babu S, Lichtenstein F, West K, Sivakumar S, Menon PA, Viswanathan V, Andrade BB, Nakaya HI, Kornfeld H. Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications. Sci Rep. 2017 May 17;7(1):1999. PMCID: PMC5435727

  7. Rockwood N, Costa DL, Amaral EP, Bruyn ED, Kubler A, Gil-Santana L, Fukutani KF, Scanga CA, Flynn JL, Jackson SH, Wilkinson KA, Bishai WR, Sher A, Wilkinson RJ, Andrade BB. Mycobacterium tuberculosis induction of heme oxygenase-1 expression is dependent on oxidative stress and reflects treatment outcomes. Front Immunol. 2017 May 12. PMCID: PMC5427075

  8. Huaman MA, Kryscio RJ, Fichtenbaum CJ, Henson D, Salt E, Sterling TR, Garvy BA. Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis. Epidemiol Infect. 2017 May;145(7):1363-1367. doi: 10.1017/S0950268817000279. Epub 2017 Feb 16. PMID: 28202093; PMCID: PMC5616129

  9. Bordelon H, Ricks KM, Pask ME, Russ PK, Solinas F, Baglia ML, Short PA, Nel A, Blackburn J, Dheda K, Zamudio C, Cáceres T, Wright DW, Haselton FR, Pettit AC. Design and use of mouse control DNA for DNA biomarker extraction and PCR detection from urine: Application for transrenal Mycobacterium tuberculosis DNA detection. J Microbiol Methods. 2017 May;136:65-70. doi: 10.1016/j.mimet.2017.02.010. Epub 2017 Mar 9. PMID: 28285168; PMCID: PMC5421388

  10. Otero L, Villegas L, Huamán M, Sterling T, Seas C. The need for randomised controlled trials of isoniazid monoresistant tuberculosis treatment. Lancet Infect Dis. 2017 Apr;17(4):363-364. doi: 10.1016/S1473-3099(17)30121-4. PMID: 28346171

  11. Miranda P, Gil-Santana L, Oliveira MG, Mesquita ED, Silva E, Rauwerdink A, Cobelens F, Oliveira MM, Andrade BB, Kritski A. Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation. PLoS One. 2017 Apr 6;12(4):e0175278. doi: 10.1371/journal.pone.0175278. PMID: 28384354; PMCID: PMC5383283

  12. Ellis H, Mulder C, Valverde E, Poling A, Edwards T. Reproducibility of African giant pouched rats detecting Mycobacterium tuberculosis. BMC Infect Dis. 2017 Apr 24;17(1):298. doi: 10.1186/s12879-017-2347-3. PMID: 28438117; PMCID: PMC5402322

  13. Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S. Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. Int J Tuberc Lung Dis. 2017 Mar 1;21(3):286-296. doi: 10.5588/ijtld.16.0469. Epub 2017 Jan 13. PMID: 28087928; PMCID: PMC6563818

  14. McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities. Int J Infect Dis. 2017 Mar;56:194-199. doi: 10.1016/j.ijid.2016.11.423. Epub 2016 Dec 9. PMID: 27955992; PMCID: PMC5606236

  15. Clouse K, Blevins M, Lindegren ML, Yotebieng M, Nguyen DT, Omondi A, Michael D, Zannou DM, Carriquiry G, Pettit A; International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration. Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in the International epidemiologic Databases to Evaluate AIDS (IeDEA) program. PLoS One. 2017 Feb 9;12(2):e0171384. doi: 10.1371/journal.pone.0171384. PMID: 28182705; PMCID: PMC5300213

  16. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan 15;64(2):111-115. doi: 10.1093/cid/ciw778. PMID: 28052967; PMCID: PMC5504475

  17. Manion M, Andrade BB, DerSimonian R, Gu W, Rupert A, Musselwhite LW, Sierra-Madero JG, Belaunzaran-Zamudio PF, Sanne I, Lederman MM, Sereti I. Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patients. J Virus Erad. 2017 Jan 1;3(1):24-33. PMID: 28275455; PMCID: PMC5337418

  18. Geadas C, Stoszek SK, Sherman D, Andrade BB, Srinivasan S, Hamilton CD, Ellner J. Advances in basic and translational tuberculosis research: Proceedings of the first meeting of RePORT international. Tuberculosis (Edinb). 2017 Jan;102:55-67. doi: 10.1016/j.tube.2016.11.006. Epub 2016 Nov 27. PMID: 28061953

  19. Arlehamn CS, Copin R, Leary S, Mack SJ, Phillips E, Mallal S, Sette A, Blatner G, Siefers H, Ernst JD; TBRU-ASTRa Study Team. Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 100 Luo infants from the Boro area of Nyanza Province, Kenya. Hum Immunol. 2017 Apr;78(4):325-326. Epub 2017 Mar 16. PMID: 28315719; PMCID: PMC5519768

  20. Pavlos R, Redwood A, Phillips E. AdDRESSing T-cell responses to antituberculous drugs. Br J Dermatol. 2017 Feb;176(2):292-293. PMID: 28244076; PMCID: PMC5429398

  21. Gelbard A, Katsantonis NG, Mizuta M, Newcomb D, Rotsinger J, Rousseau B, Daniero JJ, Edell ES, Ekbom DC, Kasperbauer JL, Hillel AT, Yang L, Garrett CG, Netterville JL, Wootten CT, Francis DO, Stratton C, Jenkins K, McGregor TL, Gaddy JA, Blackwell TS, Drake WP. Molecular analysis of idiopathic subglottic stenosis for Mycobacterium species. Laryngoscope. 2017 Jan;127(1):179-185. doi: 10.1002/lary.26097. Epub 2016 Jun 14. PMID: 27295947; PMCID: PMC5156582

  22. Carvalho ES, de Souza AW, Leão SC, Levy-Neto M, de Oliveira RS, Drake W, de Franco MF, Saldiva PH, Gutierrez PS, Andrade LE. Absence of mycobacterial DNA in peripheral blood and artery specimens in patients with Takayasu arteritis. Clin Rheumatol. 2017 Jan;36(1):205-208. doi: 10.1007/s10067-016-3400-0. Epub 2016 Sep 7. PMID: 27604701; PMCID: PMC5742422

2016

  1. Sterling TR. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016 Dec 1;20(12):42-47. PMID: 28240572

  2. Eilertson B, Maruri F, Blackman A, Herrera M, Sterling TR. Reversion of phenotypic fluoroquinolone resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2016 Sep;20(9):1276-7. PMID: 27510259.

  3. Eilertson B, Maruri F, Blackman A, Guo Y, Herrera M, van der Heijden Y, Shyr Y, Sterling TR. A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2016 Sep;71(9):2419-27. PMCID: PMC4992850

  4. Buchacz K, Lau B, Jing Y, Bosch R, Abraham AG, Gill MJ, Silverberg MJ, Goedert JJ, Sterling TR, Althoff KN, Martin JN, Burkholder G, Gandhi N, Samji H, Patel P, Rachlis A, Thorne JE, Napravnik S, Henry K, Mayor A, Gebo K, Gange SJ, Moore RD, Brooks JT; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis. 2016 Sep 15;214(6):862-72. PMID: 27559122

  5. Russ PK, Karhade AV, Bitting AL, Doyle A, Solinas F, Wright DW, Haselton FR. A Prototype Biomarker Detector Combining Biomarker Extraction and Fixed Temperature PCR. J Lab Autom. 2016 Aug;21(4):590-8. doi: 10.1177/2211068216634072. Epub 2016 Feb 26. PMID: 26920577

  6. Pettit AC, Mendes A, Jenkins C, Napravnik S, Freeman A, Shepherd BE, Dowdy D, Gill J, Rachlis A, Moore R, Sterling TR; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) investigators of International epidemiologic Databases to Evaluate AIDS (IeDEA). Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):572-8. PMCID: PMC4942351

  7. Edwards TL, Valverde E, Mulder C, Cox C, Poling A. Pouched rats as detectors of tuberculosis: comparison to concentrated smear microscopy. Eur Respir J. 2016 Aug;48(2):579-82. doi: 10.1183/13993003.00264-2016. Epub 2016 Jun 10. PMID: 27288036

  8. Rotsinger JE, Celada LJ, Polosukhin VV, Atkinson JB, Drake WP. Molecular Analysis of Sarcoidosis Granulomas Reveals Antimicrobial Targets. Am J Respir Cell Mol Biol. 2016 Jul;55(1):128-34. doi: 10.1165/rcmb.2015-0212OC. PMID: 26807608; PMCID: PMC4942207

  9. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016 Jun 19;30(10):1607-15. doi: 10.1097/QAD.0000000000001098. PMID: 27243774; PMCID: PMC4899978

  10. Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, Scott NA, Shang N, Kerrigan A, Goldberg SV. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis. 2016 Jun 1;62(11):1390-1400. doi: 10.1093/cid/ciw126. Epub 2016 Mar 6. PMID: 26951571; PMCID: PMC6521957

  11. Charles MK, Lindegren ML, Wester CW, Blevins M, Sterling TR, Dung NT, Dusingize JC, Avit-Edi D, Durier N, Castelnuovo B, Nakigozi G, Cortes CP, Ballif M, Fenner L; International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration. Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One. 2016 Apr 13;11(4):e0153243. PMCID: PMC4830552

  12. Villegas L, Otero L, Sterling TR, Huaman MA, Van der Stuyft P, Gotuzzo E, Seas C. Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. PLoS One. 2016 Apr 5;11(4):e0152933. PMCID: PMC4821555

  13. Aldred KJ, Blower TR, Kerns RJ, Berger JM, Osheroff N. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E839-46. doi: 10.1073/pnas.1525055113. Epub 2016 Jan 20. PMID: 26792518; PMCID: PMC4763725

  14. Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 2016 Jun;81(6):1030-6. Epub 2016 Feb 25. PMID: 26773235; PMCID: PMC4876174.

2015

  1. Huaman MA, Henson D, Ticona E, Sterling TR, Garvy BA. Tuberculosis and Cardiovascular Disease: Linking the Epidemics. Trop Dis Travel Med Vaccines. 2015;1. pii: 10. Epub 2015 Oct 30. PMCID: PMC4729377.

  2. Hamilton CD, Swaminathan S, Christopher DJ, Ellner J, Gupta A, Sterling TR, Rolla V, Srinivasan S, Karyana M, Siddiqui S, Stoszek SK, Kim P. RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration. Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S155-9. doi: 10.1093/cid/civ611. PMID: 26409277; PMCID: PMC4583572

  3. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, Grant AD, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, Van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015 Sep 24. pii: ERJ-01245-2015. PMID:26405286

  4. Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829. PMID: 26260821; PMCID: PMC5080618

  5. Sterling TR. Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment. Evid Based Med. 2015 Aug;20(4):128-9. PMID: 25926523

  6. Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, Weis S, Ho C, Villarino ME; Tuberculosis Trials Consortium. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015 Aug 15;61(4):527-35. doi: 10.1093/cid/civ323. Epub 2015 Apr 22. PMID: 25904367; PMCID: PMC4560029.

  7. Creecy A, Russ PK, Solinas F, Wright DW, Haselton FR. Tuberculosis Biomarker Extraction and Isothermal Amplification in an Integrated Diagnostic Device. PLoS One. 2015 Jul 1;10(7):e0130260. doi: 10.1371/journal.pone.0130260. PMID: 26132307; PMCID: PMC4488445

  8. Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW; Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15;60(12):1860-3. doi: 10.1093/cid/civ155. Epub 2015 Feb 26. PMID: 25722197; PMCID: PMC4542662

  9. van der Heijden YF, Heerman WJ, McFadden S, Zhu Y, Patterson, B. (2015). Missed Opportunities for Tuberculosis Screening in Primary Care. Journal of Pediatrics. 2015 May; 166(5): 1240-5. PMCID: PMC4414729

  10. van der Heijden YF, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR. (2015). A Comparison of Interview Methods to Ascertain Fluoroquinolone Exposure Before Tuberculosis Diagnosis. Epidemiology and Infection. 2015 Apr; 143(5), 960-5. PMCID: PMC4352378

  11. Huaman MA, Fiske CT, Jones TF, Warkentin J, Shepherd BE, Ingram LA, Maruri F, Sterling TR. Tuberculosis and the risk of infection with other intracellular bacteria: a population-based study. Epidemiol Infect. 2015 Apr;143(5):951-9. PMCID: PMC4336842

  12. Ballif M, Renner L, Claude Dusingize J, Leroy V, Ayaya S, Wools-Kaloustian K, Cortes CP, McGowan CC, Graber C, Mandalakas AM, Mofenson LM, Egger M, Kumara Wati KD, Nallusamy R, Reubenson G, Davies MA, Fenner L; International Epidemiologic Databases to Evaluate AIDS (IeDEA); International Epidemiologic Databases to Evaluate AIDS IeDEA. Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. J Pediatric Infect Dis Soc. 2015 Mar;4(1):30-8. doi: 10.1093/jpids/piu020. Epub 2014 Mar 28. PMID: 26407355; PMCID: PMC5654358

  13. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878. PMID: 25580725; PMCID: PMC6624831

  14. Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H; TSHEPISO Study Team. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis. 2015 Jan 15;211(2):197-205. doi: 10.1093/infdis/jiu429. Epub 2014 Jul 31. Erratum in: J Infect Dis. 2015 Jul 1;212(1):169. PMID: 25081933; PMCID: PMC4334832

  15. Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW; ACTG A5311 Study Team. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30. PMID: 25824215; PMCID: PMC4432148

2014

  1. Ballif M, Nhandu V, Wood R, Dusingize JC, Carter EJ, Cortes CP, McGowan CC, Diero L, Graber C, Renner L, Hawerlander D, Kiertiburanakul S, Du QT, Sterling TR, Egger M, Fenner L; International epidemiological Databases to Evaluate AIDS (IeDEA). Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries. Int J Tuberc Lung Dis. 2014 Nov;18(11):1327-36. doi: 10.5588/ijtld.14.0106. PMID: 25299866; PMCID: PMC4323497

  2. Menzies D, Sterling TR. Treatment of Mycobacterium tuberculosis infection: time to get a move on? Ann Intern Med. 2014 Sep 16;161(6):449-50. PMID: 25111391

  3. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2014 Jun;58(6):3270-5. doi: 10.1128/AAC.02066-13. Epub 2014 Mar 31. PMID: 24687490; PMCID: PMC4068501

  4. Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME; Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group. Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc. 2014 Jun;3(2):132-45. doi: 10.1093/jpids/pit077. Epub 2014 Jan 16. PMID: 26625366.

  5. Fiske CT, Yan FX, Hirsch-Moverman Y, Sterling TR, Reichler MR; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk factors for treatment default in close contacts with latent tuberculous infection. Int J Tuberc Lung Dis. 2014 Apr;18(4):421-7. doi: 10.5588/ijtld.13.0688. PMID: 24670696; PMCID: PMC4060979

  6. Huaman MA, Sterling TR, Shepherd BE, Fiske CT. 25-Hydroxyvitamin D levels after recovery from tuberculosis: Insights into pathogenesis. Tuberculosis (Edinb). 2014 Jan;94(1):51-4. PMCID: PMC3938285

2013

  1. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013 Dec;17(12):1531-7. doi: 10.5588/ijtld.13.0423. PMID: 24200264; PMCID: PMC5451112

  2. Person AK, Pettit AC, Sterling TR. Diagnosis and treatment of latent tuberculosis infection: an update. Curr Respir Care Rep. 2013 Dec; 2(4):199-207. PMCID: PMC4185413

  3. Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR; Tuberculosis Epidemiologic Studies Consortium. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect. 2013 Nov;67(5):424-32. doi: 10.1016/j.jinf.2013.07.015. Epub 2013 Jul 8. PMID: 23845828; PMCID: PMC3788833

  4. Fenner L, Ballif M, Graber C, Nhandu V, Dusingize JC, Cortes CP, Carriquiry G, Anastos K, Garone D, Jong E, Gnokoro JC, Sued O, Ajayi S, Diero L, Wools-Kaloustian K, Kiertiburanakul S, Castelnuovo B, Lewden C, Durier N, Sterling TR, Egger M; International epidemiological Databases to Evaluate AIDS (IeDEA). Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One. 2013 Oct 17;8(10):e77697. doi: 10.1371/journal.pone.0077697. PMID: 24147059; PMCID: PMC3798412.

  5. Cortes CP, Wehbe FH, McGowan CC, Shepherd BE, Duda SN, Jenkins CA, Gonzalez E, Carriquiry G, Schechter M, Padgett D, Cesar C, Madero JS, Pape JW, Masys DR, Sterling TR; Caribbean, Central American, South American Network for HIV Research of the International Epidemiologic Databases to Evaluate AIDS. Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis. PLoS One. 2013 Sep 16;8(9):e74057. doi: 10.1371/journal.pone.0074057. PMID: 24066096; PMCID: PMC3774609

  6. van der Heijden YF, Maruri F, Blackman A, Mitchel E, Bian A, Shintani AK, Eden S, Warkentin JV, Sterling TR. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. Int J Antimicrob Agents. 2013 Sep;42(3):232-7. doi: 10.1016/j.ijantimicag.2013.04.027. Epub 2013 Jun 24. PMID: 23806638; PMCID: PMC3780576

  7. McIlleron HM, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry C, Smith P, Haas DW, Maartens G. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS. 2013 Jul 31;27(12):1933-40. doi: 10.1097/qad.0b013e328360dbb4. PMID: 24180002; PMCID: PMC3879806

  8. Bordelon H, Russ PK, Wright DW, Haselton FR. A magnetic bead-based method for concentrating DNA from human urine for downstream detection. PLoS One. 2013 Jul 8;8(7):e68369. doi: 10.1371/journal.pone.0068369. PMID: 23861895; PMCID: PMC3704639

  9. Chang KC, Sterling TR, Yew WW. Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis? Int J Tuberc Lung Dis. 2013 Jun;17(6):712. PMID: 23676152

  10. Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JA, Sterling TR. Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS. 2013 May 15;27(8):1321-9. PMCID: PMC3992322

  11. Pettit AC, Cummins J, Kaltenbach LA, Sterling TR, Warkentin JV. Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis. Int J Tuberc Lung Dis. 2013 Apr;17(4):486-92. doi: 10.5588/ijtld.12.0133. Epub 2013 Feb 7. PMID: 23394818; PMCID: PMC3981539

  12. Richmond BW, Ploetze K, Isom J, Chambers-Harris I, Braun NA, Taylor T, Abraham S, Mageto Y, Culver DA, Oswald-Richter KA, Drake WP. Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-γ expression. J Clin Immunol. 2013 Feb;33(2):446-55. doi: 10.1007/s10875-012-9817-6. Epub 2012 Oct 18. PMID: 23073617; PMCID: PMC3850764

2012

  1. Hiatt LA, Cliffel DE. Real-time Recognition of Mycobacterium tuberculosis and Lipoarabinomannan using the Quartz Crystal Microbalance. Sens Actuators B Chem. 2012 Nov 1;174:245-252. doi: 10.1016/j.snb.2012.06.095. Epub 2012 Aug 19. PMID: 23175600; PMCID: PMC3500912

  2. Oswald-Richter KA, Beachboard DC, Seeley EH, Abraham S, Shepherd BE, Jenkins CA, Culver DA, Caprioli RM, Drake WP. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol. 2012 Oct;32(5):1129-40. doi: 10.1007/s10875-012-9700-5. Epub 2012 May 3. PMID: 22552860; PMCID: PMC3526106

  3. Blackman A, May S, Devasia RA, Maruri F, Stratton C, Sterling TR. Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance. Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2177-82. doi: 10.1007/s10096-012-1552-7. Epub 2012 Feb 10. PMID: 22322359; PMCID: PMC3981548

  4. van der Heijden YF, Maruri F, Blackman A, Holt E, Warkentin JV, Shepherd BE, Sterling TR. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int J Tuberc Lung Dis. 2012 Sep;16(9):1162-7. doi: 10.5588/ijtld.12.0046. Epub 2012 Jul 12. PMID: 22794509; PMCID: PMC3981533

  5. Kernodle DS. Warning: differences in the copy number of duplication unit 2 (DU2) within BCG Danish 1331 may influence findings involving genetically modified BCG Danish strains. Vaccine. 2012 Sep 14;30(42):6013-4; author reply 6015. doi: 10.1016/j.vaccine.2012.01.023. Epub 2012 Feb 10. PMID: 22326901

  6. Person AK, Sterling TR. Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep. 2012 Sep;9(3):259-66. doi: 10.1007/s11904-012-0120-1. PMID: 22581360; PMCID: PMC3410968

  7. Fiske CT, de Almeida AS, Shintani AK, Kalams SA, Sterling TR. Abnormal immune responses in persons with previous extrapulmonary tuberculosis in an in vitro model that simulates in vivo infection with Mycobacterium tuberculosis. Clin Vaccine Immunol. 2012 Aug;19(8):1142-9. doi: 10.1128/CVI.00221-12. Epub 2012 Jun 6. PMID: 22675156; PMCID: PMC3416084

  8. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270. doi: 10.1371/journal.pmed.1001270. Epub 2012 Jul 24. PMID: 22911011; PMCID: PMC3404110

  9. Fiske CT, Griffin MR, Mitchel E, Sterling TR, Grijalva CG. Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):666-9. doi: 10.1002/pds.3243. Epub 2012 Apr 24. PMID: 22532509; PMCID: PMC3371104

  10. Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol. 2012 Apr;50(4):1390-6. doi: 10.1128/JCM.05286-11. Epub 2011 Dec 21. PMID: 22189117; PMCID: PMC3318526

  11. Sterling TR, Moro R, Villarino ME. Reply to: "Rifapentine and Isoniazid for Latent Tuberculosis". N Engl J Med. 2012 Apr 12;366(15):1448. PMID: 31166682; PMCID: PMC6634941

  12. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012 Apr;67(4):819-31. doi: 10.1093/jac/dkr566. Epub 2012 Jan 25. PMID: 22279180; PMCID: PMC3299416

  13. Kernodle DS. SigH, antioxidants, and the pathogenesis of pulmonary tuberculosis. J Infect Dis. 2012 Apr 15;205(8):1186-8. doi: 10.1093/infdis/jis108. Epub 2012 Mar 7. PMID: 22402036

  14. Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C; ACTG 5267 Study Team. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):455-62. doi: 10.1097/QAI.0b013e3182410503. PMID: 22126739; PMCID: PMC3302922

  15. Antas P, Holland S, Sterling T. Abnormal spontaneous interleukin 8 receptor expression: a brief report of two cases. Rev Soc Bras Med Trop. 2012 Feb;45(1):134-7. doi: 10.1590/s0037-86822012000100029. PMID: 22370847; PMCID: PMC3981535.

  16. de Almeida AS, Fiske CT, Sterling TR, Kalams SA. Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin Vaccine Immunol. 2012 Jan;19(1):45-52. doi: 10.1128/CVI.05263-11. Epub 2011 Oct 28. PMID: 22038848; PMCID: PMC3255960

2011

  1. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875. PMID: 22150035

  2. Kipp AM, Pungrassami P, Stewart PW, Chongsuvivatwong V, Strauss RP, Van Rie A. Study of tuberculosis and AIDS stigma as barriers to tuberculosis treatment adherence using validated stigma scales. Int J Tuberc Lung Dis. 2011 Nov;15(11):1540-5, i. doi: 10.5588/ijtld.10.0273. PMID: 22008770; PMCID: PMC3753693

  3. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis. 2011 Sep 15;204(6):893-901. doi: 10.1093/infdis/jir421. PMID: 21849286; PMCID: PMC3156918

  4. Kipp AM, Pungrassami P, Nilmanat K, Sengupta S, Poole C, Strauss RP, Chongsuvivatwong V, Van Rie A. Socio-demographic and AIDS-related factors associated with tuberculosis stigma in southern Thailand: a quantitative, cross-sectional study of stigma among patients with TB and healthy community members. BMC Public Health. 2011 Aug 30;11:675. doi: 10.1186/1471-2458-11-675. PMID: 21878102; PMCID: PMC3223813

  5. Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, Raffanti SP, Shepherd BE, Sterling TR. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):305-10. doi: 10.1097/QAI.0b013e3182182e2d. PMID: 21423024; PMCID: PMC3141096

  6. Manier ML, Reyzer ML, Goh A, Dartois V, Via LE, Barry CE 3rd, Caprioli RM. Reagent precoated targets for rapid in-tissue derivatization of the anti-tuberculosis drug isoniazid followed by MALDI imaging mass spectrometry. J Am Soc Mass Spectrom. 2011 Aug;22(8):1409-19. doi: 10.1007/s13361-011-0150-8. Epub 2011 May 13. PMID: 21953196; PMCID: PMC3424619

  7. Pettit AC, Kaltenbach LA, Maruri F, Cummins J, Smith TR, Warkentin JV, Griffin MR, Sterling TR. Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. Int J Tuberc Lung Dis. 2011 Jul;15(7):906-11. doi: 10.5588/ijtld.10.0448. PMID: 21682963; PMCID: PMC3172045

  8. Murphree R, Warkentin JV, Dunn JR, Schaffner W, Jones TF. Elephant-to-human transmission of tuberculosis, 2009. Emerg Infect Dis. 2011 Mar;17(3):366-71. doi: 10.3201/eid1703.101668. PMID: 21392425; PMCID: PMC3166032

  9. Swaisgood CM, Oswald-Richter K, Moeller SD, Klemenc JM, Ruple LM, Farver CF, Drake JM, Culver DA, Drake WP. Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide. Am J Respir Cell Mol Biol. 2011 Feb;44(2):166-74. doi: 10.1165/rcmb.2009-0350OC. Epub 2010 Mar 26. PMID: 20348207; PMCID: PMC3049230.

  10. Oki NO, Motsinger-Reif AA, Antas PR, Levy S, Holland SM, Sterling TR. Novel human genetic variants associated with extrapulmonary tuberculosis: a pilot genome wide association study. BMC Res Notes. 2011 Jan 31;4:28. doi: 10.1186/1756-0500-4-28. PMID: 21281516; PMCID: PMC3041678

  11. Bukka A, Price CT, Kernodle DS, Graham JE. Mycobacterium tuberculosis RNA Expression Patterns in Sputum Bacteria Indicate Secreted Esx Factors Contributing to Growth are Highly Expressed in Active Disease. Front Microbiol. 2012 Jan 10;2:266. doi: 10.3389/fmicb.2011.00266. PMID: 22291682; PMCID: PMC3254194

2010

  1. Chambers IR, Cone TR, Oswald-Richter K, Drake WP. Enzyme-linked immunospot assay (ELISPOT): Quantification of Th-1 cellular immune responses against microbial antigens. J Vis Exp. 2010 Nov 23;(45):2221. doi: 10.3791/2221. PMID: 21178951; PMCID: PMC3159592

  2. Oswald-Richter KA, Beachboard DC, Zhan X, Gaskill CF, Abraham S, Jenkins C, Culver DA, Drake W. Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis. Respir Res. 2010 Nov 23;11(1):161. doi: 10.1186/1465-9921-11-161. PMID: 21092305; PMCID: PMC2999599

  3. Richmond BW, Drake WP. Vitamin D, innate immunity, and sarcoidosis granulomatous inflammation: insights from mycobacterial research. Curr Opin Pulm Med. 2010 Sep;16(5):461-4. doi: 10.1097/MCP.0b013e32833af7e8. PMID: 20473167

  4. Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Int J Infect Dis. 2010 Sep;14 Suppl 3:e60-6. doi: 10.1016/j.ijid.2009.11.012. Epub 2010 Mar 1. PMID: 20189863; PMCID: PMC2905608

  5. Oswald-Richter KA, Drake WP. The etiologic role of infectious antigens in sarcoidosis pathogenesis. Semin Respir Crit Care Med. 2010 Aug;31(4):375-9. doi: 10.1055/s-0030-1262205. Epub 2010 Jul 27. PMID: 20665387

  6. Kernodle DS. Decrease in the effectiveness of Bacille Calmette-Guérin vaccine against pulmonary tuberculosis: a consequence of increased immune suppression by microbial antioxidants, not overattenuation. Clin Infect Dis. 2010 Jul 15;51(2):177-84. doi: 10.1086/653533. PMID: 20524854

  7. Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis. 2010 May 15;50 Suppl 3:S223-30. doi: 10.1086/651495. PMID: 20397952

  8. Motsinger-Reif AA, Antas PR, Oki NO, Levy S, Holland SM, Sterling TR. Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med Genet. 2010 Mar 2;11:37. doi: 10.1186/1471-2350-11-37. PMID: 20196868; PMCID: PMC2837863

  9. Light RW. Update on tuberculous pleural effusion. Respirology. 2010 Apr;15(3):451-8. doi: 10.1111/j.1440-1843.2010.01723.x. Epub 2010 Mar 21. PMID: 20345583

  10. Kernodle DS, Sadagopal S, Kalams SA. Re: Misleading comments in Ranganathan et al. "Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice". Vaccine. 2010 Feb 25;28(9):2064-5. doi: 10.1016/j.vaccine.2009.12.029. Epub 2009 Dec 25. PMID: 20038429

  11. Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, Weinfurter P; Tuberculosis Epidemiologic Studies Consortium. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010 Feb;137(2):401-9. doi: 10.1378/chest.09-0394. Epub 2009 Sep 30. PMID: 19793865

  12. Oswald-Richter K, Sato H, Hajizadeh R, Shepherd BE, Sidney J, Sette A, Newman LS, Drake WP. Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101. J Clin Immunol. 2010 Jan;30(1):157-66. doi: 10.1007/s10875-009-9311-y. Epub 2009 Jun 18. PMID: 19536643; PMCID: PMC2821522

  13. Fiske CT, Griffin MR, Erin H, Warkentin J, Lisa K, Arbogast PG, Sterling TR. Black race, sex, and extrapulmonary tuberculosis risk: an observational study. BMC Infect Dis. 2010 Jan 22;10:16. doi: 10.1186/1471-2334-10-16. PMID: 20096113; PMCID: PMC2823615